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Introduction
Importance of genus Candida in contemporary medicine
Among the fungi of medical interest, yeasts of the genus 
Candida are of great importance because of the high frequency 
that they colonize and infect human hosts. Candida species 
are found in the gastrointestinal tract in 20-80% of healthy 
adults. Approximately 20-30% of women have vaginal Candida 
colonization.1 these commensal micro-organisms become 
pathogenic when there are changes in the mechanisms 
of host defense or when anatomical barriers secondary to 
burns are compromised or invasive medical procedures 
occur. Changes in host defense mechanisms may be due to 
physiological changes in childhood (prematurity) and aging 
but are more often associated with degenerative diseases, 
malignancies, congenital or acquired immunodeficiencies 
and immunosuppression induced by drugs and medical 
procedures.2
In the medical community, oral candidiasis and vaginitis 
caused by Candida account for a significant number of clinical 
complaints brought to colleagues of different specialties. 
Candida is the predominant genus among the yeasts of 
the autochthonous microbiota of the oral cavity and other 
segments of the gastrointestinal tract. the prevalence of oral 
cavity colonization by yeasts in normal individuals varies, 
but most authors report rates of approximately 20-40% in 
the general population.3 Among the 20 species of Candida of 
medical importance, Candida albicans is the most prevalent 
yeast in the oral cavity (accounting for more than 90% 
of isolates), along with other sites of colonization by this 
fungus. If there is a disruption of local defense mechanisms, 
metabolic dysfunction or the presence of diseases associated 
with immunosuppression, the colonized subject can develop 
infection and disease.1 Currently, oral candidiasis is the most 
prevalent opportunistic infection among patients living with 
AIDS; it is considered a marker of the progression of the 
immunological deterioration that affects this population. 
Among treatment-naïve patients infected with human 
immunodeficiency virus (HIV) or those with no response 
to highly active anti-retroviral therapy, episodes of oral 
candidiasis usually become recurrent and may progress to 
esophagitis.4
Vulvovaginal candidiasis is the second leading cause of 
infectious leucorrhea. It is responsible for approximately 13 
million cases of vaginitis documented annually in north 
American patients. Surveys reveal that 75% of women 
experience an episode of vaginal candidiasis during 
childbearing years, with the estimation that 5% of these 
women have recurrent episodes.5 Candida vulvovaginitis 
can be sporadic or recurrent, and infections are termed 
primary or secondary according to the presence or absence 
of comorbidities associated with this condition. Primary 
vulvovaginitis is idiopathic and accounts for the vast 
majority of cases. Secondary vulvovaginitis can have different 
causes, including hormonal imbalances, metabolic disorders, 
medications (i.e., antibiotics, contraceptives) and diseases 
associated with immunosuppression.6
In the hospital environment, Candida infections account for 
80% of all fungal infections, including bloodstream, urinary 
tract and surgical site infections. Pulmonary infections 
caused by Candida are poorly documented in clinical practice.7 
Bloodstream infections are now a major challenge for 
tertiary hospitals worldwide due to their high prevalence 
and mortality rates.8 the incidence of candidemia in tertiary 
public hospitals in Brazil is approximately 2.5 cases per 1000 
hospital admissions, a rate considered two to ten times higher 
than those registered in European and American hospitals and 
similar to the rates in neighboring countries.9-11
In addition to infection in the bloodstream, urinary 
candidiasis is common in hospitalized patients. this 
laboratory finding is controversial, as it may reflect different 
clinical possibilities that range from a simple contamination 
of biological material at the time of collection to a colonization 
of the urinary tract, sepsis or localized invasive disease caused 
by Candida spp. In most cases, candiduria involves colonization 
but not urinary infection.12
Diversity of the genus Candida and its clinical relevance
the genus Candida has become recognized as the nomen 
conservandum, first at the International Botanical Congress held 
in Montreal in 1959. this genus consists of approximately 200 
species, of which about 20 have been linked to cases of human 
mycosis.2 Most of the yeasts have no known sexual form, and 
identification at the species level is obtained by analyzing their 
micromorphological characteristics and biochemical profiles. 
Morphological characterization of the majority of isolates of 
this genus consists of the observation of its capacity to produce 
blastoconidia, pseudo-hyphae (sometimes true hyphae) and 
eventually chlamydospores (Candida albicans and Candida 
dubliniensis). In fact, Candida spp. have great genetic diversity 
and distinct morphological and biochemical characteristics 
but traditionally have been classified in the same genus.13
Despite the large number of Candida species already 
described, the main species of clinical interest are Candida 
albicans, Candida parapsilosis, Candida tropicalis, Candida glabrata, 
Candida krusei, Candida guilliermondii and Candida lusitaniae. 
However, several cases of superficial and invasive diseases and 
emerging species of Candida have been described, involving 
isolates of Candida dubliniensis, Candida kefyr, Candida rugosa, 
Candida famata, Candida utilis, Candida lipolytica, Candida 
norvegensis and Candida inconspicua, among others.14 Recently, 
molecular tools have been used in the revision of the taxonomy. 
these tools are essential for the characterization of some 
species as agents of emerging infections in the human host, 
including Candida dubliniensis, Candida pseudorugosa, Candida 
metapsilosis and Candida orthopsilosis; these last two were 
associated with the complex “psilosis”, formerly characterized 
as Candida parapsilosis genotypes I, II and III.15,16
Candida albicans is undoubtedly the most frequently isolated 
species of superficial and invasive infections at different 
anatomical sites and in studies worldwide. It is well-known 
as a potentially pathogenic yeast exhibiting pathogenicity and 
virulence factors including the capacity to adhere to epithelia 
and various mucous membranes, dimorphism-producing 
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filamentous structures that assist in tissue invasion, significant 
thermotolerance and the production of enzymes such as 
proteases and phospholipases.17 this species is naturally 
sensitive to all systemic antifungal drugs, but cases of acquired 
resistance to azoles have been reported in patients who 
have prolonged exposure to these drugs; additionally, few 
isolates resistant to echnocandins have been also reported.18 
Resistance to amphotericin B is considered anecdotal.19
Candida dubliniensis has been recognized as a new species 
whose morphological and biochemical characteristics are 
very similar to those of Candida albicans. Molecular tests are 
needed to differentiate the two species. this new species 
was first described in Ireland, where 17-35% of patients 
with HIV infection have oral colonization or infection with 
Candida dubliniensis.20 In a Brazilian study that evaluated 548 
yeast samples stored in a mycology yeast collection, it was 
determined that 2% of samples originally identified as Candida 
albicans were actually Candida dubliniensis.21 this emerging 
species seems to be less pathogenic than Candida albicans, but 
it has a high probability of developing resistance to azoles.22
Candida parapsilosis is an important agent of candidemia 
and is responsible for 15-30% of candidemias in most series 
published in Brazil.9,23 In the northern Hemisphere, the 
occurrence is higher among children and premature newborns, 
but Candida parapsilosis in Brazil can be found in all age 
groups.24 the frequency of Candida parapsilosis varies between 
public and private hospitals in Brazil but is prevalent in the 
public setting.25,26 Characteristically, Candida parapsilosis grows 
in glucose solution, has great capacity to produce “biofilm” 
and often colonizes the skin of health professionals. Several 
studies have reported outbreaks of candidemia due to Candida 
parapsilosis associated with the presence of a central venous 
catheter and the use of parenteral nutrition.27 Clinical isolates 
of this species are usually sensitive to amphotericin B and 
triazoles.22 However, data generated by the SEntRY – a global 
candidemia surveillance network – identified some samples of 
Candida parapsilosis resistant to fluconazole.28 High minimum 
inhibitory concentration (MIC) values for echinocandins have 
been described against clinical isolates of Candida parapsilosis. 
However, in most cases, these values are still within the 
range of susceptibility to this class of drugs.29 In comparative 
clinical trials performed with caspofungin, micafungin and 
anidulafungin, the three echinocandins available for clinical 
use, their therapeutic results for infections caused by Candida 
parapsilosis were similar to those obtained with infections 
caused by Candida albicans.30-32 Aside from a clinical study 
conducted by Moura-Duarte et al. that observed a higher 
number of cases of persistent candidemia due to Candida 
parapsilosis in patients treated with caspofungin than those 
treated with amphotericin B, the rate of therapeutic success 
obtained for infections caused by Candida parapsilosis was 
similar to the rate for Candida albicans infections.30 thus 
far, in this context, although some authors suggest that 
there is a possibility of rebound infections caused by Candida 
parapsilosis in patients exposed to echinocandins, data from 
clinical trials indicate that echinocandins have good efficacy 
in Candida parapsilosis infections.33-35 An important aspect to be 
considered regarding Candida parapsilosis is the recent change 
in the taxonomy: due to the sequencing of different essential 
genes of clinical isolates of Candida parapsilosis, tavanti et 
al. characterized the genetic heterogeneity of this taxon. 
As a result, “complex psilosis” was reclassified to include 
three species: Candida parapsilosis, Candida orthopsilosis and 
Candida metapsilosis.15 It is still not completely understood the 
biological differences that may be presented by species within 
the “complex psilosis”. However, the isolates from the three 
species may exhibit differences in patterns of susceptibility 
to antifungal agents and biofilm production.16,36
Candida tropicalis is a potential opportunistic agent when 
the host is neutropenic and when there is suppression 
of bacterial flora due to antibiotic use and damage to the 
gastrointestinal mucosa. Candida tropicalis is the second or 
third most common etiologic agent of candidemia in patients 
with cancer, particularly leukemia, and less frequently in 
patients with solid tumors.37 In Brazil, unlike countries in 
Europe and in the United States, Candida tropicalis accounts 
for a substantial number of documented cases of candidemia 
in non-neutropenic patients or patients with cancer.9,23,25,26,38,39 
Clinical isolates of this species are susceptible to amphotericin 
B and most of the azoles. However, some authors have 
documented the occurrence (usually <5%) of isolates resistant 
to fluconazole. Considering that this species has a strong 
phenomenon of partial inhibition of growth in in vitro tests 
(trailing), there is some doubt as to whether the rates of in 
vitro resistance to fluconazole is overestimated.40
Candida glabrata has emerged as an important hospital 
pathogen, representing the second or third most common 
species among the agents of candidemia reported in medical 
centers in Europe and the United States.41 In Latin America, 
data generated from case series documented until 2005 show 
that the isolation of Candida glabrata candidemia accounted 
for no more than 5-8% of all episodes of fungemia in public 
hospitals.9,42 Recently, data from cohorts of private hospitals 
and medical centers that perform large numbers of organ 
transplants, where the practice of prophylaxis with fluconazole 
in high risk patients seems to be more common, indicate that 
the prevalence of Candida glabrata among the causative agents 
of fungemia reaches more than 10% of the cases.43 Clinical 
isolates of Candida glabrata are less susceptible to fluconazole. 
Most series documented that 50% of Candida glabrata strains 
have reduced susceptibility to fluconazole and that 10-20% of 
strains are resistant to this drug.44 Consequently, increases in 
the rates of colonization/infection by Candida glabrata have 
been observed in different groups of patients exposed to 
fluconazole.45 In addition to therapeutic issues with azoles 
in infections associated with Candida glabrata, Pfaller et al. 
observed that isolates of Candida glabrata may have lower in 
vitro susceptibility to amphotericin B and suggested the need 
for higher doses of polienic for the treatment of invasive 
infections caused by this agent.46 Another epidemiologic 
aspect of this pathogen is its high prevalence in elderly 
patients. In a multicenter study, which evaluated samples of 
candidemia in 17 medical centers in the state of Iowa, it was 
observed that Candida glabrata is more prevalent in elderly 
patients and accounted for 25% of all fungemias documented 
in patients over 65 years.47
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Candida krusei is an occasional hospital pathogen that 
is particularly isolated from patients with hematologic 
malignancies and/or who are undergoing allogeneic 
hematopoietic stem cell transplant (HSCt).48 Some authors 
reported increased occurrence of fungemias caused by Candida 
krusei in neutropenic patients exposed to prolonged courses of 
fluconazole.37 this yeast is naturally resistant to fluconazole, 
but in most cases, it is sensitive to voriconazole (cross-
resistance is uncommon in this species).49
Invasive infections caused by Candida guilliermondii are 
still infrequent, although there are several case reports, 
especially in patients with cancer.50 Despite the lack of 
information available in the literature, there are reports of 
in vitro resistance of clinical samples of Candida guilliermondii 
to amphotericin B, triazoles and echinocandins. the clinical 
relevance of these in vitro data is still debated; thus, clinical 
and laboratory monitoring of patients treated with these drugs 
is recommended to identify treatment failure.51
Candida lusitaniae is infrequently a causative agent of 
invasive disease but has been reported as a candidemia 
agent in immunocompromised patients. From a total of 86 
reported cases of invasive disease by this species, 70 were 
identified in patients with cancer. often, clinical isolates of 
Candida lusitaniae have primary or secondary resistance to 
amphotericin B, but they are very sensitive to all triazoles.52
the epidemiological and therapeutic peculiarities presented 
by different species of Candida spp. justify the need to identify 
yeast at the species level when these micro-organisms 
are associated with systemic diseases. this procedure is 
fundamental for choosing the best therapeutic approach to 
be administered to patients. In summary, it is important 
to note that Candida krusei isolates are completely resistant to 
fluconazole and that, more often than other species (except 
Candida krusei), Candida glabrata samples can be resistant to or 
can require higher doses of azoles for successful treatment. 
Likewise, higher doses of amphotericin B should be used in the 
treatment of invasive infections caused by Candida krusei and 
Candida glabrata. Finally, clinical isolates of Candida lusitaniae 
may be resistant to amphotericin B.28,46 
In this context, it is important to recognize that, for the 
clinician, the support of mycological diagnostics is essential 
for the prevention, control and treatment of Candida infections. 
Complete identification of yeast species is necessary; this 
information is essential not only for the definition of therapeutic 
choice but also for the control of hospital infection rates at 
different sites and during the investigation of outbreaks.1 In 
this sense, it is important to know the wide range of manual 
and automated commercial systems available that allow rapid 
and accurate identification of yeasts of clinical interest.53 these 
guidelines suggest that all medical centers that treat patients 
at risk for developing invasive fungal infections must have 
a microbiology laboratory able to identify the main fungal 
species of medical interest. there is no technical, medical 
or administrative element that supports the clinical staff of 
tertiary hospitals for working in medical centers without the 
basic support of mycological diagnosis.
With regards to susceptibility testing, in view of discussions 
concerning the existing clinical validation of cutoff points for 
different therapeutic classes and the difficulty of access to 
this test for most medical centers in Brazil, it is not possible 
to recommend its universal use. therefore, the best scientific 
evidence available on clinical-laboratory susceptibility tests 
was generated by in vitro assays performed with Candida 
species and fluconazole.44,54
thus, the indication for antifungal susceptibility testing 
has been evaluated in two different scenarios: during 
epidemiological investigation and while assisting the clinician 
at the bedside. In the first scenario, susceptibility tests are 
needed for surveillance studies of species distribution and 
for monitoring MICs for different antifungal drugs in several 
hospital facilities. this allows us to identify and characterize 
temporal trends and the geographic emergence of pathogens 
resistant to different drugs, thus supporting a safe indication 
of empirical therapy.55
While at the bedside, there are four indications for 
performing susceptibility testing with azole: a) to evaluate 
the susceptibility to antifungal agents in patients with 
hematogenous candidiasis with poor response to the drug 
in use, information that, along with species identification, 
is important for guiding a possible change in regimen; b) 
to evaluate the susceptibility to fluconazole in a sample of 
Candida spp. isolated from invasive infections in the event 
that this triazole was started empirically; c) to shorten the 
time therapy started with echinocandin or a lipid formulation 
of amphotericin B, introducing sequential therapy with oral 
fluconazole (de-escalation); and d) for superficial infections 
with Candida glabrata or other Candida strains that may be 
resistant to fluconazole and to assess the possible in vitro 
activity of a new oral triazole, such as voriconazole.56
If the medical center decided to make the clinical results of 
in vitro antifungal susceptibility tests available, testing should 
be performed by reference laboratories using standardized 
methodology from regulatory authorities such as the CLSI and 
EUCASt, or using methods known to be equivalent to these 
tests, such as E-tESt and Vitek-2.57-60
Therapeutic options for infections caused by Candida spp.
During the last decade, the traditional therapeutic compounds, 
consisting mainly of polienic, imidazole and first-generation 
triazoles, have been expanded with the development and 
validation of new systemic antifungal agents. Among the new 
antifungal agents active against Candida spp. developed in the 
last decade, we highlight the second-generation triazoles and 
a novel class of antifungal agents, the echinocandins.
Polienic
nystatin and amphotericin B are natural antifungals 
discovered in the 1950s and obtained from aerobic bacteria 
(Streptomyces noursey and Streptomyces nodosus, respectively) 
that have broad-spectrum antifungal activities. In Candida 
infections, nystatin is reserved for superficial infections due to 
its topical action. Amphotericin B is indicated for severe forms 
of invasive candidiasis. the primary mechanism of action is 
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the interaction with steroid components of the cell membranes 
of eukaryotic cells, leading to rupture. other mechanisms have 
been suggested, such as the production of oxygen free radicals 
by phagocytes in the host. there are different formulations of 
amphotericin B for intravenous infusion: a deoxycholic acid 
formulation (amphotericin B deoxycholate or conventional) 
and lipid formulations (colloidal dispersion, lipid complex 
and liposomal). the safest lipid formulations in clinical use 
are amphotericin B lipid complex and liposomal formulation; 
the latter has lower toxicity and greater tolerability compared 
to the former formulation.61
Conventional amphotericin B is primarily associated with 
acute infusion events, including fever, chills, nausea, vomiting, 
bronchospasm and rash. Fewer side effects are experienced 
with the lipid complex formulation (two-hour infusion) 
and particularly with the liposomal formulation (one-hour 
infusion). the most serious adverse effects are related to the 
nephrotoxicity of conventional amphotericin B, including the 
deterioration of renal, cardiac and hematopoietic functions. 
of these, renal failure is the most common, occurring in 12-
80%, depending on the criteria adopted for renal failure and 
the population evaluated.62 Among the various alternatives 
to reduce nephrotoxicity, hydration with 500 mL of isotonic 
saline solution produces better results without compromising 
effectiveness, but it can be limited in critically ill patients.63 
Among the lipid formulations of amphotericin B, the liposomal 
formulation causes a lower incidence of nephrotoxicity.64,65
Amphotericin B is fungicidal and is active against various 
Candida species. Secondary resistance is rare. there are data 
suggesting that amphotericin B MICs for Candida glabrata and 
Candida krusei are higher, requiring the use of higher doses 
of polienic. there is evidence that primary and/or secondary 
resistance to amphotericin B can occur with clinical isolates 
of Candida lusitaniae.66,67
Azoles
the azoles are a therapeutic class of great clinical utility 
because of their broad spectrums of action (especially 
voriconazole and posaconazole), their safety and the 
availability of oral and intravenous formulations (fluconazole 
and voriconazole). this therapeutic class can be divided into 
two groups: the imidazoles and triazoles. the first imidazole 
with topical action, clotrimazole, launched in 1960, and it is 
still being used for superficial candidiasis. In turn, the triazole 
compounds are subdivided into first-generation (itraconazole 
and fluconazole) and second-generation (voriconazole and 
posaconazole) compounds. Isavuconazole, a new second-
generation triazole, is still under clinical investigation.68
the azole derivatives are characterized by their selective 
inhibition of the production of ergosterol, a steroid found 
in the fungal cell membrane. their mode of action is the 
inhibition of fungal 14-α-demethylase, a cytochrome 
p450-dependent enzyme. Its catalyzing process is essential 
for the conversion of lanosterol into ergosterol. other actions 
that can contribute to the antifungal activity have been 
described, such as inhibition of the yeast transformation 
into mycelium, the decrease in fungal cell adhesion and the 
accumulation of steroids that are potentially toxic to fungal 
cells once the conversion of lanosterol into ergosterol is 
blocked.69,70 Mechanisms of resistance related to drug efflux, 
as described with Candida glabrata, invariably lead to cross-
resistance. Mutations in the gene ERG-11 and changes in the 
target enzyme 14-α-demethylase, as described with Candida 
krusei and fluconazole, may not cause cross-resistance, as the 
second-generation triazoles (voriconazole and posaconazole) 
have higher avidity for the target enzyme.71 Recently, there has 
been discussion regarding harmonization of the breakpoints 
of susceptibility to fluconazole, and the MIC value limit for 
susceptible strains was decreased to 2 µg/mL for Candida 
albicans, Candida parapsilosis and Candida tropicalis.72,73
Because the triazoles are cleared via the hepatic metabolism, 
many drug interactions are possible.
Ketoconazole
Ketoconazole was the first imidazole developed for oral 
therapy of fungal infections. It has a wide spectrum of 
action against agents of dermatomycoses, endemic mycoses 
(including paracoccidioidomycosis and histoplasmosis) and 
isolates of Candida spp. Given its limited efficacy in systemic 
fungal infections in immunocompromised hosts and its 
toxicity (hepatotoxicity and depression of steroidogenesis), 
this drug was replaced by fluconazole and itraconazole in 
most indications (first-generation triazole).69
Itraconazole
Itraconazole is a soluble triazole that is available in capsule 
form. Its intravenous formulation and oral solution, both in 
cyclodextrin, are not currently available in Brazil. Although 
it can be used for infections caused by Candida, the primary 
indication is for mild to moderate endemic mycoses, such as 
paracoccidioidomycosis, histoplasmosis, coccidioidomycosis, 
blastomycosis, chromoblastomycosis, phaeohyphomycosis 
and sporotrichosis, in addition to dermatomycosis.74,75 
Because it is well tolerated in long-term use, and considering 
its excellent availability in keratinized and subcutaneous 
tissues, itraconazole can be used in chronic mucocutaneous 
candidiasis and onychomycosis. It is considered an alternative 
drug in cases of oral and vaginal candidiasis. Considering that 
only the capsule formulation is available in Brazil, itraconazole 
is not indicated for treatment of hematogenous candidiasis 
and other invasive forms of mycosis.76
Fluconazole
Fluconazole is a water-soluble triazole for parenteral 
(200 mg) and oral use (100 mg and 150 mg) that has 
antifungal activity against dermatophytes, Cryptococcus 
neoformans and most Candida spp., except for Candida krusei, 
which has primary resistance, and Candida glabrata, which 
has a lower susceptibility to fluconazole, particularly when 
isolated from patients with prior exposure to this antifungal. 
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Fluconazole has an excellent safety profile, good absorption 
in the gastrointestinal tract and distribution in different 
compartments of the body, including the central nervous 
system and the eyes. Fluconazole is effective in the treatment of 
superficial and deep infections by Candida spp., including cases 
of oroesophageal candidiasis, hematogenous candidiasis and 
candiduria and its complications.77 Most cases of toxicity to 
fluconazole are related to drug-induced hepatitis and are often 
asymptomatic. GI intolerance is not frequent, and leukopenia 
and thrombocytopenia are rare. Unlike ketoconazole, there 
is no blockage in hormonal synthesis with fluconazole. the 
dose should be reduced patients with creatinine clearance 
<50 mL/min.78
Voriconazole
Voriconazole is a triazole available in tablets of 50 mg and 
200 mg and vials of 200 mg for intravenous administration 
whose carrier is cyclodextrin. It has a broader spectrum of 
action than fluconazole, and it is active against Candida species 
that include Candida glabrata and Candida krusei, Cryptococcus 
neoformans, Trichosporon sp., Aspergillus spp., Fusarium spp., 
Scedosporium apiospermum, Histoplasma capsulatum, Blastomyces 
dermatitidis, Coccidioides immitis and Paracoccidioides brasiliensis. 
It is not active against Scedosporium prolificans and agents of 
mucormycosis. the oral formulation has good bioavailability 
and allows for safe sequential therapy and therapeutic levels 
in different tissues, including the central nervous system. 
Dose adjustments are needed in cases of moderate hepatic 
impairment, and the risks-benefits should be measured in 
severe forms of liver failure. Renal elimination of the active 
form is minimal, with no need for dose adjustment when 
using the oral formulation. However, the use of the intravenous 
form must be evaluated on a case-by-case basis in patients 
with creatinine clearance under 50 mL/min, as the excipient 
(cyclodextrin) can be accumulated in patients with renal 
failure. Regarding safety, the main adverse effects are transient 
visual disturbances (up to 30% of patients) reversible with 
discontinuation of the drug, elevations of transaminases and 
bilirubin, skin reactions and photosensitivity (up to 25%); with 
use, it is recommended to avoid sun exposure and/or to use 
sunscreen.79
In the treatment of esophageal candidiasis, voriconazole 
has clinical efficacy similar to fluconazole. Although its use is 
most important in invasive aspergillosis, in a study with non-
neutropenic patients with candidemia or invasive candidiasis, 
voriconazole exhibited similar efficacy and less renal toxicity 
compared to conventional amphotericin B followed by 
fluconazole.80,81
Posaconazole
Posaconazole is a triazole whose chemical struc ture has 
been modified from the itraconazole molecule. this azole 
has a broad antifungal spectrum that acts in vitro and in vivo 
against isolates of Candida spp., including Candida krusei and 
some isolates of Candida glabrata resistant to fluconazole, 
Aspergillus spp., Fusarium spp., dematiaceous fungi and 
some agents of mucormycosis. to date, posaconazole is only 
available in an oral solution that is administered three to 
four times per day. the absorption can decrease in certain 
conditions, such as when the patient is receiving a proton 
pump inhibitor. An oral formulation in tablet form with a 
single daily administration and improved absorption and an 
intravenous formulation are under development. While the 
main indication is prophylaxis of fungal infections in patients 
with acute myelogenous leukemia and myelodysplastic 
syndrome receiving remission-inducing therapy as well as 
transplant recipients of allogeneic hematopoietic stem cells 
with chronic graft-versus-host disease, the triazole treatment 
is also indicated as a rescue treatment in several fungal 
infections, including oropharyngeal candidiasis. However, its 
unique availability in an oral suspension formulation may be 
a limitation for patients who are clinically unstable and/or 
with problems swallowing and absorbing drugs that require 
oral treatment.82 this drug is not yet available for clinical use 
in Brazil.
Echinocandins
Echinocandins are a new class of antifungal exclusively for 
parenteral use that are classified as inhibitors of the enzyme 
complex 1,3-β-D-glucan synthase, which synthesizes 1,3-β-D-
glucan, an essential polysaccharide component of the fungal 
cell wall. the echinocandins are rapidly fungicidal for Candida 
species and fungistatic for Aspergillus species.83 Currently, 
three drugs represent this therapeutic class: caspofungin, 
micafungin and anidulafungin.
By acting on an exclusive structure of fungal cells (the cell 
wall), the echinocandins are currently among the most safe 
and well-tolerated drugs. When present, the adverse effects 
are mild, such as fever, phlebitis at the infusion site and 
transient elevation of liver enzymes. In addition to fever, other 
symptoms mediated by histamine release may rarely occur, 
including rash, facial swelling, pruritus, sensation of warmth 
and bronchospasm. Given the small hepatic metabolism of 
these drugs, few (caspofungin and micafungin) or no drug 
interactions (anidulafungin) occur with the use of these 
drugs.83
Caspofungin
Caspofungin has been available for clinical use in Brazil for 
almost a decade. Its formulation is available in vials of 50 mg 
and 70 mg. the dose needed for invasive candidiasis is 70 mg, 
followed by 50 mg daily. the elimination of the drug occurs 
by spontaneous hydrolysis and acetylation in the liver; it does 
not undergo oxidative metabolism by the cytochrome complex 
P450-dependent enzyme, which explains its low interference 
with other drugs metabolized in the liver. this antifungal has 
no renal elimination; therefore, dose adjustment in patients 
with renal failure is not indicated. In cases of moderate hepatic 
failure, it is recommended to use a low dosage (35 mg/day in 
adults). there are no clinical data regarding its use in patients 
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with severe hepatic impairment. It has good distribution in 
different body fluids and tissues, and its concentration is 
limited in the cerebrospinal fluid, urine and eyes.84 Caspofungin 
has a large plasma protein binding capacity. this drug should 
not be used in pregnant women, and there is little clinical 
information regarding pediatric indications; however, case 
series suggest that it is an effective and safe choice even in 
this group.85 Caspofungin has been evaluated in patients with 
candidemia and/or invasive candidiasis in a randomized trial 
comparing conventional amphotericin B, which had the same 
success rate and lower toxicity.30
Anidulafungin
this echinocandin is available in vials of 100 mg. Among the 
few randomized clinical trials available for this drug, two 
studies have validated its clinical use in esophageal candidiasis 
and invasive candidiasis/candidemia, both in comparison to 
fluconazole. In the candidemia/invasive candidiasis study, 
anidulafungin was one of the few antifungal drugs that 
yielded the best therapeutic result versus the comparator 
(fluconazole) in a clinical study involving patients with 
(Cont.)
candidemia.32 Experiences with anidulafungin in the pediatric 
population, in which the safety and efficacy of caspofungin 
and micafungin have been demonstrated, are very limited.86,87 
this echinocandin has less hepatic metabolism and may 
be indicated for patients with moderate or severe hepatic 
impairment without any need for dose adjustment.88
Micafungin
this drug has been sold in vials of 100 mg for several years in 
Japan and has recently begun being sold in the U.S. and Brazil. 
Among the echinocandins, micafungin is the drug involved in 
the largest number of phase II and III studies involving patients 
with candidiasis. In candidemia and invasive candidiasis, 
studies were compared to liposomal amphotericin B and 
caspofungina.31,89 Unlike other echinocandins, micafungin 
does not require a loading dose for treatment initiation.90
Dosage and drug interactions of antifungals
tables 1 and 2 show the pharmacological aspects and 
antifungal dosages for systemic use.
Table 1 – Pharmacological aspects of systemic antifungals
Name Tissue distribution Drug interactions Adverse events
Amphotericin B and 
lipidic formulations
Broad
High concentrations in 
lungs, liver, spleen
Low concentration in CnS
Ciclosporin, aminoglycosides, foscarnet, 
pentamidine, antineoplastic (renal toxicity)
Infusion reactions (fever, chills, 
hypotension, thrombophlebitis)
Renal toxicity
(<lipidic formulation)
Hypokalemia
Anemia
Itraconazole Broad
Low concentrations in 
saliva, urine and CSF
Hepatic metabolism
Inhibitors of gastric acidity (↓ absorption of 
itraconazole)
Rifampicin, carbamazepine, phenytoin, 
phenobarbital (↓ serum)
Cyclosporine, terfenadine, astemizole, 
cisapride, warfarin, digoxin, lovastatin, 
simvastatin (↑ serum)
nausea, vomiting
Increase in transaminases
Fluconazole Broad
High concentrations in 
CnS, aqueous humor and 
prostate
Urinary clearance (active 
metabolites)
Rifampicin, phenytoin, carbamazepine
(↓ level of fluconazole)
nausea, vomiting 
transient increase in transaminases
Voriconazole Broad
High concentrations in CnS, 
liver and adrenal cortex
Liver metabolism
terfenadine, astemizole, cisapride, 
ergot alkaloids, quinidine, tacrolimus, 
cyclosporine, omeprazole
(↑ serum)
Sirolimus
(↑ concentration of voriconazole)
Rifampicin, carbamazepine and 
phenobarbital
(↓ concentrations of voriconazole)
transient visual disturbances
transient increase in transaminases
Photosensitivity
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Table 1 – Pharmacological aspects of systemic antifungals (cont.)
Name Tissue distribution Drug interactions Adverse events
Caspofungin Broad
Low concentrations in CnS 
and urine
Cyclosporine
(↑ caspofungin concentration)
Rifampin, efavirenz, nevirapine, phenytoin, 
dexamethasone, carbamazepine 
(↓ caspofungin concentration)
Reactions related to infusion (fever, 
chills, rash, thrombophlebitis)
Anidulafungin Broad
Low concentrations in CnS 
and urine
not described transient increase in transaminases
Micafungin Broad
Low concentrations in CnS 
and urine
Itraconazole, sirolimus and nifedipine
(↑ serum)
Table 2 – Antifungal dosages in humans based on renal function
Name Regular dosage Cl >50 Cl between 10 and 50 Cl <10
Amphotericin B 0.5 – 1 mg/kg/day QD 0.5 – 1 mg/kg/day QD 0.5 – 1 mg/kg/day QD
Amphotericin B  
Lipidic formulation
3 – 5 mg/kg/day QD 3 – 5 mg/kg/day QD 3 – 5 mg/kg/day QD
Itraconazole 100 – 200 mg/day BID 100 – 200 mg/day BID 100 – 200 mg/day BID
Fluconazole 800 mg/day BID – 1 day 
(loading dose)
200 – 400 mg/day BID
400 mg/day BID – 1 day 
(loading dose)
100 – 200 mg/day BID
400 mg/day BID – 1 day 
(loading dose)
100 – 200 mg/day QD
Voriconazole 6 mg/kg/day BID – 2 days 
(loading dose)
4 mg/kg/day BID 
(maintenance)
* 6 mg/kg/day BID – 2 days 
(loading dose)
4 mg/kg/day BID 
(maintenance)
* 6 mg/kg/day BID – 2 days 
(loading dose)
4 mg/kg/day BID 
(maintenance)
Caspofungin 70 mg/day QD – 1 day 
(loading dose)
50 mg/day QD 
(maintenance)
70 mg/day QD – 1 day 
(loading dose)
50 mg/day QD 
(maintenance)
70 mg/day QD – 1 day 
(loading dose)
50 mg/day QD 
(maintenance)
Anidulafungin 200 mg/day QD – 1 day 
(loading dose)
100 mg/day QD 
(maintenance)
200 mg/day QD – 1 day 
(loading dose)
100 mg/day QD
(maintenance)
200 mg/day QD – 1 day 
(loading dose)
100 mg/day QD 
(maintenance)
Micafungin 100 mg/day QD 100 mg/day QD 100 mg/day QD
Cl, creatinine clearance (mL/min)
*  Avoid the use of IV voriconazole in patients with creatinine clearance <50 mL/min (toxicity risk). there are no restrictions for use of the oral 
formulation in cases of renal failure.
Below, we discuss the treatment of major infections caused 
by Candida. the therapeutic recommendations are indicated for 
adult patients and were based on levels of evidence according to 
the strength of the recommendation and the quality of evidence 
from the American Society of Infectious Diseases, adapted from 
the Canadian Ministry of Health,91 as shown in table 3.
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Table 3 – Strength of recommendation and quality of evidence
Category Definition
Strength of recommendation
 A Strong evidence to support recommendation
 B Moderate evidence to support recommendation
 C Poor evidence to support recommendation
Quality of evidence
 I Evidence of ≥ 1 randomized controlled clinical trial 
 II Evidence of ≥ 1 well-designed clinical trial, not randomized, cohort or 
case-control studies (preferably more than one center), or multiple sets of 
results of uncontrolled studies 
 III Evidence based on expert opinion or clinical experience, descriptive 
studies or committee reports
Clinical and laboratory diagnosis
Clinical manifestations are varied and depend on the host’s 
immune status and the extent of oral candidiasis. the 
largest clinical experience of infectious disease is in the 
form of pseudomembranous candidiasis. the most common 
symptoms are oral discomfort, burning pain and the presence 
of removable white plaque under erythematous mucosa. these 
conditions make feeding difficult, and they can compromise 
the regularity of oral drug treatments.97 However, other clinical 
presentations are known. Erythematous candidiasis presents 
itself as erythematous infiltrate with reduced papillae when 
present on the tongue. Patients using dental prostheses with 
oral candidiasis have chronic erythema and discomfort in the 
region of the prosthesis. Angular cheilitis caused by Candida 
spp. manifests as discomfort, erythema, and fissures in the 
angular region of the lips.98
the clinical presentation is usually very characteristic of 
this condition, particularly when it is pseudomembranous. 
However, clinical diagnosis should be confirmed by laboratory 
investigation as follows: a) by direct mycological examination, 
with scrapes of lesions in KoH preparations or by Gram 
staining, where the specimen is analyzed by the presence of 
fungal elements consistent with Candida spp.; and/or b) by 
culturing in selective fungal medium (preferably chromogenic 
medium to identify different species), where the yeast is 
isolated and the agent is forwarded to complete identification.99
Culture is particularly important in cases of recurrent 
candidiasis in patients with AIDS, in cases of poor response 
to conventional therapy or when an injury that is suggestive 
of candidiasis arises in patients receiving any antifungal drug. 
In these situations, the identification of the agent species and 
testing for susceptibility to antifungal agents are necessary 
recommendations for optimizing a new therapeutic indication 
in view of the possibility of infection by strains of Candida spp. 
resistant to one or all triazoles.100-101
Each topography was discussed with regards to 
epidemiological, clinical and laboratory diagnostic and 
therapeutic recommendations. In Appendix 1 is summarized 
the therapeutic options for treating candidiasis.
Treatment
Oral candidiasis
Epidemiological aspects
oral candidiasis is considered superficial candidiasis that affects 
patients with changes in local or systemic immunity, either 
due to age (premature neonates and the elderly), prosthesis 
use, exposure to immunosuppressive drugs (chemotherapy, 
corticosteroids), antibiotics or the presence of diseases such as 
cancer, diabetes, sarcoidosis, cirrhosis, malnutrition, xerostomy 
and AIDS.92 In clinical practice, most cases of candidiasis are 
observed in pediatric patients, who exhibit immaturity of 
the defense mechanisms of the mucosa, and the elderly, 
whose defense mechanisms are senescent or even because 
of the use of dental prostheses.93 the pathological conditions 
most commonly associated with oral candidiasis in adult 
patients are AIDS, diabetes and exposure to antibiotics and/
or corticosteroids for different conditions. therefore, all adult 
patients presenting with oral candidiasis without obvious cause 
should be investigated for HIV infection.94
Candida albicans accounts for approximately 90% of the 
isolates causing oroesophageal candidiasis, but Candida 
tropicalis, Candida krusei, Candida glabrata, Candida parapsilosis 
and Candida dubliniensis can also be detected.95 In AIDS 
patients unresponsive to antiretroviral therapy, episodes 
of oropharyngeal candidiasis become recurrent, requiring 
prolonged use or repeated cycles of therapy with triazoles. In 
this scenario, there is an increase in episodes of candidiasis 
by Candida non-albicans isolates resistant to fluconazole or even 
in the risk of selecting resistant strains of Candida albicans to 
this drug.96
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Therapeutic recommendations
the goal of treatment is to eliminate the signs and symptoms 
of the disease, reduce or eliminate colonization and prevent 
recurrence.92 topical therapy is recommended for patients 
without HIV/AIDS (B-I) and for the initial episodes of 
cryptococcosis in patients with HIV/AIDS (A-I).
Topical therapy (uncomplicated infection)
•   Nystatin 100.000-400.000 IU/mL and 4-6 mL four to five 
times a day for 14 days (B-II). Successful treatment 
depends on the time of contact with the oral mucosa 
for at least two minutes. It is worth mentioning that 
this drug has a low tolerance and high sugar content as 
a vehicle. It also has cariogenic potential and should be 
used with caution in diabetic patients.98
•   In the U.S. and Europe, an oral clotrimazole solution is 
available for use three to five times a day for 14 days (B-II). 
In these countries, topical therapy is the rule in mild 
and/or early candidiasis, even in patients with AIDS.102 
Unfortunately, in Brazil, clotrimazole is not available in 
formulations suitable for oral use. In this context, in view 
of the difficulties in handling nystatin, topical therapy is 
restricted to only a few patients.
Systemic therapy
the best therapeutic option for systemic candidiasis is oral 
fluconazole; the other options are considered only in patients 
unresponsive or intolerant to this drug (A-I).100
•   Fluconazole 200 mg PO in the first day and 100 mg/day 
for 7 to 14 days (A-I). 
In patients with oropharyngeal candidiasis refractory to 
fluconazole, the options are as follows:
•   Itraconazole 200 mg orally BID with food for 7-14 days 
(A-II).103,104 Considering that in Brazil we do not have an 
oral solution, capsules have the disadvantage of impaired 
absorption and less exposure of the antifungal agent in 
saliva (B-III).
•   Voriconazole 200 mg BID for 7-14 days. This drug has been 
validated in comparative clinical trials with fluconazole 
in patients with esophageal candidiasis (A-I).105 Its use in 
oral therapy for oropharyngeal candidiasis refractory to 
fluconazole is based on in vitro studies, but with limited 
documentation of their clinical success for this specific 
condition (B-II).
•   Posaconazole 200 mg PO on the first day followed by 100 
mg orally QD for 13 days for primary therapy (A-I) or 400 
mg tID for three days, followed by 400 mg QD for 25 days 
for refractory cases (B-II). this drug has been validated 
for this indication in two clinical trials: a randomized 
comparison with fluconazole and an open study for 
refractory cases.106,107 Its indication should be reserved 
for cases of poor response to fluconazole (B-I). this drug 
is not available in Brazil.
•   Amphotericin  B  deoxycholate  0.3-0.5 mg/kg/day  IV  for 
7-14 days (B-II).108 this drug should be reserved for cases 
refractory to fluconazole (B-II).
•   Caspofungin 50 mg/day IV or anidulafungin 100 mg/day 
IV or micafungin 150 mg/day IV for 7-14 days. these 
drugs have been validated in clinical trials comparing 
fluconazole in patients with esophageal candidiasis 
(A-I).109-111 the use of these drugs should be reserved 
for treatment of esophageal candidiasis refractory to 
fluconazole (B-I).
Given that oral candidiasis is related to the imbalance 
between the colonizing agent and the local or systemic 
defense mechanisms, we should try to act toward control of 
the underlying disease and/or removal of the predisposing 
conditions. otherwise, the trend favors chronicity of the 
process, as it occurs in patients with prostheses and AIDS, 
that is unresponsive to antiretroviral therapy.
Esophageal candidiasis
Epidemiological aspects
Esophageal candidiasis is considered a form of semi-
invasive candidiasis that primarily affects patients with 
AIDS, cancer, diabetes, previous esophageal diseases, 
malnutrition and alcoholism, along with those in therapies 
using corticosteroids, antibiotics, H2 receptor antagonists 
and proton-pump inhibitors.92 In clinical practice, most cases 
of esophageal candidiasis occur in AIDS patients, followed 
by lower frequencies of diabetics and critically ill patients 
exposed to multiple antibiotic cycles.99
Clinical and laboratory diagnosis
Candida esophagitis can be oligosymptomatic, but its main 
clinical manifestations include dysphagia, odynophagia and 
retroesternal burning. In children, nausea, vomiting and 
dehydration are the main signs. Although the presence of 
concomitant oral and esophageal candidiasis is common, 
particularly in AIDS patients, the absence of oral candidiasis 
does not exclude esophagitis diagnosis. Complications 
include bleeding, perforation and stenosis.101
In AIDS patients, the diagnosis is usually made based only 
on clinical data and treatment response. However, taking into 
account many other opportunistic diseases that affect the 
esophagus in immunocompromised patients (e.g., herpes 
and cyto megalovirus), laboratory investigation is mandatory 
for a definitive diagnosis.94 Endoscopy reports often reveal 
white plaques that may or may not be accompanied by 
ulcerated lesions. Apart from the morphological findings, it is 
recommended to perform a scrap (brush) to obtain a sample 
for microscopic examination and culturing, in addition to a 
mucosal biopsy.99
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the microscopic examination of fungal elements is 
performed with a sample obtained by scraping on a slide 
with KoH or by Gram stain. the culture is performed with 
a sample obtained by scraping or biopsy. A biopsy should 
be processed with hematoxylin-eosin staining and silver 
methenamine (Grocott).99
the definitive diagnosis of esophageal candidiasis is made 
when, in addition to the clinical and morphological endoscopic 
findings, we identify fungal elements on microscopic 
examination and/or observe the presence of fungal elements 
in tissue, confirming invasion by the pathogen. From an 
academic point of view, the isolated identification of Candida 
in culture but no fungal elements by microscopic examination 
and biopsy may represent colonization of the gastrointestinal 
tract and not infection.101
Therapeutic recommendations
•   Systemic therapy is recommended for cases of esophageal 
candidiasis (B-II). this starts with empirical systemic 
therapy (A-I) with fluconazole 200 mg Po or IV in the first 
day, followed by 100 mg QD for 14-21 days (A-I). When 
endoscopy is not performed at the time of diagnosis, it 
should be performed if no improvement occurs within 
three to five days.95
In patients with esophageal candidiasis refractory to 
fluconazole, the options are as follows:
•   Voriconazole 200 mg BID for 14 to 21 days. This drug was 
validated in a comparative clinical trial with fluconazole 
in patients with esophageal candidiasis (A-I).105 Its use 
in the treatment of esophageal candidiasis refractory 
to fluconazole may have a compromised result due to 
eventual cross-resistance; however, it is a good indication 
for susceptibility tests, if available. (B-II).
•   Itraconazole 200 mg PO BID with food for 14 to 21 days 
(A-II).103,104 Given that there is no oral formulation in 
Brazil and cross-resistance is commonly observed across 
triazoles, treatment with capsules presents problems 
with absorption and lesser exposure of the drug to the 
saliva. these factors can compromise treatment success.
•   Posaconazole 200 mg PO on the first day followed by 100 
mg Po QD for 13 days for primary therapy (A-I), or 400 
mg BID for 3 days followed by 400 mg QD for 25 days 
for refractory cases (B-II). this drug was validated for 
this indication in two clinical trials: one controlled and 
randomized with fluconazole and another open-label for 
refractory cases.106,107 Its use for esophageal candidiasis 
refractory to fluconazole may be compromised by an 
eventual cross-resistance; however, it is a good indication 
for susceptibility tests, if available (B-II). this drug is not 
available in Brazil.
•   Amphotericin  B  deoxycholate  0.3-0.5 mg/kg/day  IV  for 
7-14 days (B-II).108
•   Caspofungin 50 mg/day IV or anidulafungin 100 mg/day 
IV or micafungin 150 mg/day IV for 7-14 days. these 
drugs were validated in comparative clinical trials with 
fluconazole in patients with esophageal candidiasis 
(A-I).109-111
Vulvovaginal candidiasis
Epidemiological aspects
Vaginal candidiasis is highly prevalent in women during 
their childbearing life; approximately 75% have at least one 
episode lifelong, and 5-10% can develop a recurrence (defined 
as at least four episodes of vaginitis by Candida spp. within 
one year).112
the most frequent predisposing factors for vaginal 
candidiasis include exposure to high levels of estrogens (birth 
control, pregnancy and hormone replacement), uncontrolled 
diabetes mellitus, use of topical and systemic antibiotics and 
inadequate hygiene habits. Most women with recurrent 
vaginal candidiasis do not have underlying diseases associated 
with systemic immunosuppression, and recurrence may be 
secondary to a deficiency in the local immune response to 
the agent.113
Vulvovaginal candidiasis is usually classified as complicated 
or uncomplicated, pending on the severity of the clinical 
presentation and basic conditions of the host. Uncomplicated 
forms of vaginitis account for more than 90% of cases and 
have an excellent response to short oral or topical therapy. 
Patients with more complicated vaginitis require a prolonged 
antimycotic therapy.114
Candida albicans is the most frequent cause of vaginitis, 
accounting for approximately 74-95% of cases, followed by 
Candida glabrata in approximately 14.5% of cases. the non-
albicans species are more common in recurrent forms and 
may be found in 10-20% of these patients. Candida glabrata 
is the species most frequently identified in these cases.115,116
Clinical and laboratory diagnosis
Considering that 30% of women may have Candida coloni-
zation and there is a wide differential diagnosis for infectious 
leukorrhea, the diagnosis of Candida vulvovaginitis should be 
based on clinical and laboratory findings.117
Candidiasis involves the vulva and the vaginal lumen, 
causing intense itching, burning, local discomfort, dysuria, 
vaginal discharge and dyspareunia. Clinical examination 
revealed swelling and redness of the vulva and/or vagina, 
vaginal discharge that looks like milk and, eventually, vulvar 
carved cracks.118
Clinical diagnosis must be performed by the following 
tests:117
•   Direct  microscopic  examination  with  the  addition  of 
KoH (10%) or Gram stain to search for fungal elements, 
complemented by evaluation of the vaginal pH (infection 
usually occurs with a pH between 4 and 4.5);
•   Culture  in  specific  material.  To  decrease  costs,  some 
authors recommend prompt culture only for complicated 
or recurrent vulvovaginal candidiasis.
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Therapeutic recommendations
Non-complicated vulvovaginal candidiasis
topical therapy: although most patients prefer oral medica-
tions, a meta-analysis comparing 17 studies of uncomplicated 
vulvovaginal candidiasis revealed similar efficacy between 
oral and vaginal drugs.119 there is evidence that topically 
applied azole therapy over a period of three to seven days is 
more effective than nystatin, with improvement of symptoms 
and negative cultures in 80-90% of patients who completed 
therapy (A-I). Generally, higher concentrations and doses 
of topical medications are effective over a period of three 
days. Lower doses of the same formulations require more 
prolonged therapy.102 the options for topical therapy are 
numerous and include the following:
•   Butaconazole 2% cream, 5 g/day;
•   Clotrimazole cream 1%, 5 g/day;
•   Clotrimazole vaginal tablets, 500 mg/day;
•   Miconazole 2% cream, 5 g/day;
•   Miconazole,  100 mg,  200 mg  or  1200 mg  (single  dose), 
vaginal suppositories;
•   Econazole, 150 mg, tablet or suppository;
•   Terconazole 0.4% or 0.8% cream, 5 g/day;
•   Terconazole, 80 mg, vaginal suppositories;
•   Nystatin, 100.000 IU vaginal tablets (10-14 days).
there are formulations containing combination therapy 
with other agents that will not be commented upon in the text:
•   Systemic  therapy:  the  use  of  oral  triazoles  is  a  safe  and 
efficient alternative to topical therapy. there is a large 
amount of clinical experience in treating vulvovaginal 
candidiasis with fluconazole 150 mg QD, single dose (A-I).102 
Another option to this drug is itraconazole 200 mg QD for 3 
days or 400 mg single dose (B-II).120 Systemic therapy with 
triazoles is not indicated in pregnant women. the treatment 
of sexual partners is not recommended in uncomplicated 
cases but may be considered in recurrent cases.121
Complicated vulvovaginal candidiasis
•   Moderate and severe cases and/or immunocompromised 
patients: prolonged topical and systemic therapy should 
be administered to these patients. topical therapy is 
recommended for at least 7-14 days using any of the 
formulations listed above (A-I).102 In case of systemic 
therapy, the following drugs can be considered:
•   Fluconazole 150 mg/day, repeated two or three times 72 
hours apart (A-I);
•   Itraconazole 200 mg/day for 3 days (B-II).
Recurrent vulvovaginal candidiasis
•   If the diagnosis of recurrent vulvovaginal candidiasis is 
made and if there is no identification of or possibility 
to control or remove the triggering factors, suppressive 
therapy with triazoles for six months is an effective 
control measure for recurrent episodes (A-I).122
•   In  such  patients,  attack  therapy  can  be  administered 
with any of the topical formulations listed above for 7-14 
days (A-I) or fluconazole 150 mg/day each 72 hours (days 
1, 4 and 7) or until complete symptoms remission; this 
is the preferred regimen in clinical practice. once the 
initial episode is controlled, maintenance therapy with 
fluconazole 150 mg/day once a week for six months is 
indicated (A-II).122
•   Although  the  largest  clinical  experience  of  suppressive 
therapy for recurrent candidiasis was with fluconazole 
(A-I), there are published trials that suggest maintenance 
therapy with clotrimazole 500 mg suppositories twice a 
week or itraconazole (200 mg Po twice a week or 200 mg 
Po BID monthly) (B-I).123,124
•   Cases  of  vulvovaginal  candidiasis  caused  by  Candida 
glabrata may not respond to fluconazole. In these cases, 
vaginal suppositories of boric acid 600 mg/day for 14 days 
are indicated (B-I).125
Urinary candidiasis
Epidemiological aspects
the term candiduria refers to the growth of Candida spp. in 
urine cultures collected by appropriate techniques; this finding 
is not necessarily accompanied by signs and/or symptoms of 
urinary tract infection. Candiduria is very frequent among 
patients exposed to risk factors; up to 20% of hospitalized 
patients may have candiduria during their hospitalization, 
particularly ICU (intensive care unit) patients.126,127 this 
laboratory finding fosters dilemmas regarding its inter-
pretation, as it can represent a simple contamination of 
the urine collection, candiduria asymptomatic cystitis or 
pyelonephritis, primary renal candidiasis, ureteropelvic fungus 
ball or disseminated candidiasis with renal manifestations.
Among hospitalized patients, the factors most often related 
to the development of candiduria are advanced age, female 
gender, broad-spectrum antibiotics, the use of corticosteroids 
and immunosuppressive drugs, the presence of urinary tract 
abnormalities, diabetes, delayed vesical catheterization, 
postoperative of major surgery and malignancies.127,128
Series of cases from Brazil confirm that the three most 
prevalent species isolated from urine in hospitalized patients 
are Candida albicans, Candida tropicalis and Candida glabrata. 
these studies measure prevalences ranging from 35.5 to 70% 
for Candida albicans, 4.6 to 52.5% for Candida tropicalis and 7 to 
8.8% for Candida glabrata.129-132
Clinical and laboratory diagnosis
In outpatients not exposed to the risk factors mentioned, 
in most cases, the identification of Candida in urine reflects 
inadequate collection or processing of the sample and 
consequent contamination of the culture. In patients exposed 
to risk factors for urinary tract infection by Candida, the finding 
of candiduria may signify colonization or infection. In these 
 BRAZ J INFECT DIS. 2012;16(Suppl.1):S1-S34 S13
patients, the counting of colonies is highly variable and directly 
dependent on the methodology used to collect material. thus, 
the isolation of Candida in the urine may occur even in the 
absence of disease, and there is considerable controversy 
regarding the value of colony counts obtained in culture, a 
procedure with low specificity and sensitivity in differentiating 
between patients colonized and infected by this agent.133
Some authors suggest that there is a greater relationship 
between candiduria and urinary tract infection when 
the colony count in the urine culture reaches values of 
approximately 10.000 CFU/mL to 100.000 CFU/mL.134,135 
However, scores below that can be measured in patients with 
Candida urinary tract infection (UtI), particularly in cases of 
pyelonephritis acquired by the hematogenous route due to 
systemic candidiasis, in which the kidneys function as filters 
and may reflect low counts in the urine. In this sense, there 
is no consensus among authors on the specific cutoff value 
for the interpretation of quantitative urine cultures for the 
recognition of patients with infection of the lower urinary 
tract infection or pyelonephritis.136
Therapeutic recommendations
•   The  best  therapeutic  approach  for  patients  with 
candiduria should be defined on individual bases, 
considering clinical and epidemiological data to classify 
each patient into one of the following conditions: 1) no 
prior risk factors for candiduria, 2) exposure to risk factors 
but unlikely to be a case of disseminated candidiasis, or 
3) exposure to risk factors for candiduria with septicemia 
without defining etiology and possible/probable systemic 
dissemination.102,133
•   The  therapeutic  approach  suggested  for  these  three 
different scenarios are the following. 1) no prior risk factors 
for candiduria: in this category, we have patients without 
underlying diseases who did not undergo catheterization 
and who have no history of previous use of corticosteroids 
and antibiotics. they should not receive systemic antifungal 
agents. It is recommended to request a new collection 
of material and, if yeasts are found, to investigate the 
possibility of fungal genital mucositis in the vagina or the 
glans (C-III).137 2) Predisposed to candiduria, but unlikely 
to be disseminated candidiasis: this category includes 
asymptomatic outpatients or inpatients who underwent 
catheterization and/or other predisposing factors for 
candiduria. In these patients, the initial approach is the 
removal of the predisposing factors with subsequent 
clinical and laboratory follow-up (C-III). In the vast majority 
of patients, candiduria resolves after the introduction of 
these measures. Patients with symptoms of cystitis and 
with positive urine for yeasts should be treated with 
antifungal agents (B-III).102,137 3) Predisposed to candiduria 
with probable systemic dissemination: critically ill patients 
with risk factors for systemic fungal infection and who 
evolve with candiduria and signs of sepsis should be 
investigated for invasive candidiasis (blood) and should 
begin the use of systemic antifungal drugs. this means 
that the patient is not merely colonized (C-III).102
•   If there are indications for treatment, treatment regimens 
include the following: 
–  Fluconazole, oral or intravenous dose of 200 mg/day 
for 7-14 days (A-I).138 
–  Amphotericin B, systemic dose of 0.3 mg/kg to 
1 mg/kg/day for 1-7 days (B-II) or amphotericin B, bladder 
irrigation, 50 mg/day for 48-72 hours with continuous 
infusion in a two-way tube (B-II). these schemes 
are reserved for cases refractory infections or those 
intolerant to fluconazole, along with yeasts resistant to 
this azole.102,139 
–  In case of suspicion of systemic candidiasis, the patient 
should be treated according to the recommendations 
for hematogenous candidiasis.102
–  Clinical experience with candiduria and echinocandins 
or voriconazole is restricted; pharmacological data 
suggest that the urinary concentrations of both 
antifungals are reduced.140
–  In the clinical management of patients with candiduria, 
it is important to consider the removal of the 
catheterization system, taking into account that this 
measure may resolves approximately 40% of cases, 
besides reducing the recurrence of infection (B-I).140 If 
it is not possible to remove the system, it is at least 
recommended to change it.141
Peritoneal candidiasis related to dialysis
Epidemiological aspects
Peritoneal dialysis is a modality of renal replacement therapy 
that currently accounts for only 10-20% of dialysis modalities. 
It can be performed continuously with an oriented procedure 
performed at home or intermittently, which has been completely 
abandoned. Among the complications of peritoneal dialysis, 
infection ranks second place after cardiovascular events, and 
fungal infections account for 2-14% of peritonitis cases.142 the 
overall mortality in most series ranges from 10 – 25% of cases, 
and there are a few reports of up to 50% deaths.143 Among 
the fungal peritonitis diseases, 80-90% are caused by Candida, 
particularly isolates of Candida albicans, Candida parapsilosis 
and Candida tropicalis.144 the risk factors for the occurrence 
of fungal peritonitis in patients on peritoneal dialysis are not 
completely known.145 the basic conditions most commonly 
reported in patients with fungal peritonitis include diabetes, 
the prior occurrence of peritonitis by other agents and the 
previous use of antibiotics.146
Clinical and laboratory diagnosis
Diagnosis is made through clinical signs and symptoms 
of peritonitis, which are represented by abdominal pain, 
distention, and fever associated with clouding of the dialysis 
fluid, whose cell count increases due to the neutrophil count 
(>100 leukocytes/mm3). Etiologic evidence is obtained by 
identification of yeasts in bacterioscopic examination of the 
peritoneal fluid, with growth of Candida spp. in culture.142,146
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Therapeutic recommendations
•   The guidelines for the treatment of fungal peritonitis are 
based on case reports and open-label studies of limited 
groups of patients. Among the key recommendations for 
the treatment of this complication, the authors suggest 
that the early removal of the dialysis catheter is essential 
to the success of the therapy (B-II).147
•   The  largest  experience  in  the  treatment  of  fungal 
peritonitis is with fluconazole or amphotericin B (B-II). 
Many authors recommend starting with amphotericin 
and completing treatment with fluconazole after clinical 
improvement (B-II).147
•   Some  authors  suggest  the  use  of  intraperitoneal 
fluconazole concomitantly with the systemic use of 
amphotericin B (C-III).148
•   The  treatment  period  is  usually  four  to  six weeks.  It  is 
essential to monitor the patient by abdominal ultrasound 
to rule out collections and to guide the treatment time 
(B-III).147
•   There  is  little  reliable  information  regarding  doses  of 
antifungal agents, but the authors suggest the use of 0.7 
mg/kg to 1 mg/kg/day of amphotericin B and 400 mg/day 
of fluconazole.149
•   If implantation of a new peritoneal catheter is an option, 
this procedure should be performed with a minimum 
interval of four to six weeks after the initiation of treatment 
(C-III). According to recent studies, at least 40% of patients 
with fungal peritonitis cannot continue with peritoneal 
dialysis. Another modality for renal replacement therapy 
is needed.149
•   Among the new drugs, caspofungin has experienced the 
most success. It may be considered for patients with poor 
responses to conventional treatment and can be used at 
50 mg/day to 100 mg/day with good tolerability (B-II).150 
However, in view of the pharmacological similarities and 
therapeutic success of echinocandins, it is believed that all 
echinocandins can be used with these conditions (C-III).
Postoperative peritoneal candidiasis
Epidemiological aspects
Postoperative peritonitis caused by Candida species occurs with 
significant frequency in the hospital. the majority of cases are 
related to episodes of secondary or tertiary peritonitis, when 
cases of acute abdomen perforated by bacterial peritonitis are 
subsequently followed by fungal peritonitis. the perforation of 
the upper digestive tract is more frequently associated with 
contamination of the peritoneal cavity by Candida compared to 
the ileum and appendix, occurring in 5-64% of the perforated 
cases.151
Clinical and laboratory diagnosis
the pathological significance of Candida spp. isolation in 
the peritoneal fluid and drains of patients undergoing 
surgery involving manipulation of the gastrointestinal tract 
is uncertain. the disruption of the anatomical barrier of the 
gastrointestinal tract can lead to the isolation of transitional 
agents in the abdominal cavity or contamination of cultures 
without evolution of the process to properly fungal peritonitis.152 
Moreover, a case-control study has isolated Candida spp. in 
the peritonea of patients who developed perforation of the 
gastrointestinal tract that caused increased mortality.153
In this context, the interpretation of the identification of 
Candida in peritoneal fluid should be evaluated on an individual 
basis, considering the patient’s clinical conditions. When 
Candida is identified in the peritoneal fluid of patients with 
complicated postoperative recoveries, along with persistent 
fever and other evidence of peritonitis (for which sepsis is likely 
from an abdominal source), fungal etiology should be strongly 
considered. However, in most cases when Candida is isolated 
in the intraperitoneal fluid cultures of young patients without 
comorbidities and who have no evidence of systemic infection 
in postoperative uncomplicated appendicitis, the laboratory 
finding is generally transitory with no pathological meaning.154
Therapeutic recommendations
•   Although the isolation of Candida in the abdominal cavity is 
associated with an increase in postoperative complications 
and mortality, the clinical and laboratory data that should 
trigger the use of antifungal agents are still a matter of 
controversy. If there is suspicion of invasive candidiasis, 
the patient should be treated according to the appropriate 
therapy for hematogenous candidiasis.154
•   The  most  experience  in  the  treatment  of  peritonitis 
caused by Candida involves the use of amphotericin B 
(0.7 mg/kg/day to 1 mg/kg/day) or fluconazole (400 mg/day to 
800 mg/day) (B-II).155 However, the toxicity of amphotericin 
B and the limited spectrum of fluconazole limit their use 
in many clinical scenarios.
•   Taking into account the high rate of success of treating 
hematogenous candidiasis observed in patients with 
echinocandins and the large sample of surgical patients 
in these studies, it is believed that all echinocandins 
constitute good alternatives in this condition (B-I).150,155
Respiratory tract candidiasis
Epidemiological aspects
Despite the controversies, there is a general concept in 
the literature that Candida pneumonia is an unusual event, 
particularly among non-neutropenic patients admitted 
to ICUs. the highest incidences of Candida pneumonia are 
documented among neutropenic patients with hematologic 
malignancies or patients undergoing lung transplantation.156
In most cases, Candida pneumonia is secondary to a 
hematogenous invasion. In patients undergoing lung 
transplantation, bronchial anastomosis has been identified 
as an anatomical site that is potentially more susceptible to 
colonization and invasion by opportunistic fungi, partly due to 
the relative ischemia of this region after transplantation. these 
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infections may be complicated by anastomotic dehiscence and 
subsequent bleeding.157
In ICU patients, especially those undergoing mechanical 
ventilation, airway colonization by Candida is found with 
relative frequency, but with no pathological significance. 
tracheobronchial colonization by Candida in ICU patients 
is the result of impairment of local defense mechanisms, 
the presence of an endotracheal tube, the use of antacids 
and the exposure to antibiotics, conditions that lead to 
substantial changes in the microbiota of the oropharynx and 
the gastrointestinal and respiratory tracts.158
Clinical and laboratory diagnosis
the isolation of Candida in the respiratory tract of critically 
ill patients, even if obtained by bronchoalveolar lavage, does 
not allow for the diagnosis of pulmonary candidiasis. In 
most cases, this finding refers to the colonization and/or 
contamination of the sample during the procedure. Diagnosis 
by quantitative culture is not reliable for differentiating 
colonized patients from those with pneumonia caused by 
Candida. thus, the final diagnosis is dependent on lung biopsy 
with demonstration of the presence of fungal elements in the 
intima of the parenchyma and supplemented by a culture of 
tissue fragments with growth of Candida spp.158 In practice, 
this is rarely a definitive diagnosis.
Therapeutic recommendations
•   In  general,  the  identification  of  positive  cultures  for 
Candida spp. in respiratory tract samples should be 
considered evidence of local colonization whose risk of 
progression to pneumonia is usually small (B-II).159
•   Special attention  is  recommended  in  the  investigation of 
neutropenic patients, patients with cancer or hematologic 
malignancies, along with patients undergoing hematopoietic 
stem cell transplantation or lung transplantation (B-II).160-162
•   When  a  definitive  diagnosis  of  pneumonia  is  reached, 
the antifungal should be chosen as discussed in the 
section involving acute disseminated candidiasis; there 
may be a choice between echinocandins, fluconazole or 
amphotericin B formulations (B-II).150,163
Hematogenous candidiasis
Epidemiological aspects
Hematogenous candidiasis encompasses a wide spectrum 
of clinical episodes, including isolates of Candida or cases in 
which the fungus is present in the bloodstream and spreads 
to one or more organs of the infected host.1 Considering that 
most of the data available for hematogenous Candida infection 
refer to candidemia, this is the term that will be used in these 
guidelines.
It is believed that the majority of cases of candidemia are 
acquired via the endogenous route due to the translocation 
of the pathogen through the gastrointestinal tract, where 
there is rich colonization by Candida spp. in up to 70% of the 
general population. Most candidemia events are preceded by 
colonization by the same species of yeast, which is considered 
an independent risk factor for its development. Genotyping 
methods reveal the similarities between colonizing and 
infecting strains, confirming the probable endogenous origin 
of most of the infections caused by these pathogens.164
Any variables causing injury or imbalance in the 
microbiota of the gastrointestinal mucosa can be facilitators 
of translocation of Candida spp. to the mesenteric capillaries. 
thus, factors that increase intestinal colonization by Candida 
(i.e., antibiotics, corticosteroids, ileus or intestinal obstruction) 
or that determine atrophy or intestinal mucosal damage (i.e., 
prolonged fasting, total parenteral nutrition, hypotension, 
surgical procedure, mucositis secondary to chemotherapy or 
radiotherapy) may potentiate the phenomenon of translocation 
in the gastrointestinal tract.165
Hematogenous infections by Candida spp. can also be 
acquired exogenously, either by contamination of invasive 
medical procedures, prostheses or contaminated infusion 
solutions, such as the colonization of vascular catheters in 
central positions.166
Case-control studies conducted during the 1980s and 
1990s identified numerous risk factors associated with the 
occurrence of candidemia in hospitalized patients, including: 
the use of antibiotics, colonization by Candida spp. at different 
sites, dialysis, major surgery, the use of a central venous 
catheter in place, chemotherapy, neutropenia, steroid use and 
parenteral nutrition.167,168
there is a wide geographical variation in the documented 
etiology patterns of candidemia in different medical centers. 
In different studies in tertiary hospitals in the public 
system in Brazil, Candida tropicalis and Candida parapsilosis 
are prevalent.42,169 Epidemiology can vary between different 
institutions; a recent study noted higher incidences of Candida 
glabrata in private hospitals of São Paulo, Rio de Janeiro, 
Salvador, Belo Horizonte and Curitiba, where the use of 
fluconazole started in the 1990s. Confirming these data, other 
series published after 2008 reported rates of candidemia 
due to Candida glabrata and/or Candida krusei above 10% 
in our setting.43,170 these data reinforce the importance of 
implementing programs for microbiological surveillance 
of bloodstream infections for the optimization of control 
strategies and the treatment of these infectious complications.
Clinical and laboratory diagnosis
Hematogenous candidiasis is an infectious complication that 
should always be investigated in patients with sepsis after a 
long period of hospitalization and exposure to risk factors of 
candidemia, particularly exposure to broad-spectrum antibiotic 
therapy, invasive medical procedures, immunosuppressive 
therapy and parenteral nutrition. Brazilian data suggest that 
40-50% of these patients are in the ICU at the time of 
diagnosis. A substantial number of cases have antecedents 
involving major surgery, particularly with manipulation of 
gastrointestinal tract.9,42
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the study of the natural history of patients with candidemia 
shows that some episodes of fungemia must be transient and 
self-limited, particularly in non-neutropenic hosts. However, 
there are no clinical or laboratory data that allow the clinician 
to identify with certainty which episodes are only transitory 
and which will lead to cases of disseminated hematogenous 
candidiasis with tissue invasion and severe sepsis at the 
moment of the fungemia diagnosis. Another important aspect 
to consider is that in some patients, infectious complications 
documented in the viscera appear weeks or months after 
a candidemia episode, as occurs in some cases of retinitis, 
meningitis, or osteomyelitis caused by Candida spp.171,172 
these guidelines will discuss in detail the clinical 
management of three different scenarios of hematogenous 
candidiasis:
1.  Candidemia: isolation of Candida spp. in the bloodstreams 
of patients without clinical and laboratory evidence of 
infectious foci in the viscera. In clinical practice, there 
are few cases for which there is documentation of 
the involvement of different organs during the episode 
of candidemia. the most frequent clinical pattern of 
presentation of candidemia in adults is only in the 
presence of fever that is unresponsive to antibiotics 
in patients at risk. the fever may have an insidious 
onset, without significant involvement of the general 
condition, or may be accompanied by chills, myalgia, 
hypotension and tachycardia. Eventually, some patients 
develop hypothermia and other evidence of sepsis.2
2.  Acute disseminated candidiasis: documentation of the 
presence of concomitant fungemia infection in other 
organs. When present, the acute spread of candidemia to 
the organ involves the skin and eye. However, the spread of 
infection to multiple organs may occur, including cases of 
pyelonephritis, endocarditis, osteoarticular involvement 
and involvement of the central nervous system, among 
others. the appearance of skin lesions can be the first 
clinical manifestation of invasive disease and is a marker 
of disease spread. Skin lesions may affect approximately 
8% of cases, presenting typically as small nodules or 
erythematous or purpuric maculopapules, but other 
morphological features of lesions are described. Systemic 
candidiasis with skin lesions is particularly frequent in 
neutropenic patients with candidemia due to Candida 
tropicalis.173 In more recent studies, systematic evaluation 
of fundoscopy performed by an ophthalmologist suggests 
that ocular involvement occurs in up to 16% of patients 
with candidemia, being 2 to 9% of cases of chorioretinitis 
and 1% of cases of endophthalmitis.174,175 Symptoms 
include blurred vision, bulbar scotomas and pain. the 
ophthalmologic abnormalities are characterized by cotton 
wool lesions in the retina and vitreous humor, multiple 
retinal hemorrhages, Roth spots, and uveitis. However, all 
ocular structures may be affected. When endophthalmitis 
occurs, therapy is difficult, and the incidence of sequelae 
is high. the recognition of ocular involvement in patients 
with candidemia is crucial because the treatment should 
be administered for a longer period and may eventually 
require surgery to control the process. the diagnosis 
should be made early, before the involvement of the 
vitreous.176 In adults, Candida meningitis usually results 
from the contamination of a neurosurgical procedure and 
is rarely documented as a complication of candidemia. 
However, according to data from autopsy series (which 
may not represent the general population), patients 
with sepsis who develop Candida fungal lesions in the 
central nervous system have died in up to 20% of cases.177 
Endocarditis caused by Candida usually occurs as a post-
surgical complication of valve replacement surgery and in 
intravenous drug users, particularly those who use heroin. 
Endocarditis is rarely reported as a single candidemia 
complication in a patient that did not undergo cardiac 
surgery.177 osteoarticular involvement of candidemia is 
quite rare but may arise as a late complication (more 
than one year after the alleged episode of fungemia). 
Bone involvement is recognized by local pain, fever and 
radiological findings consistent with osteomyelitis.177
the diagnosis of hematogenous candidiasis in at-risk 
patients requires careful clinical examination to identify skin 
lesions and ocular changes consistent with candidemia, in 
addition to blood cultures.
Blood cultures are a mandatory procedure in any patient 
with clinical suspicion of systemic infection by Candida, and 
some care must be taken to optimize the recovery of the agent:
•   Follow appropriate antisepsis  at  the puncture  site,  and 
remember that the antiseptic must be allowed to act for 
a few minutes before performing the collection.
•   It is desirable that blood cultures be performed before use 
of antimicrobials, or if this is not possible, blood should 
be harvested in the period preceding the administration 
of daily doses of drugs.
•   Blood volume and number of samples are crucial  for a 
good yield of blood cultures; it is recommended that at 
least two samples per episode of sepsis be collected and 
that each sample contain at least 20 mL of blood (divided 
into two blood culture bottles per sample).178
•   Conventional  aerobic  bottles  for  automated  blood 
cultures allow the growth of Candida species. However, the 
performance of aerobic vials may vary between different 
products. Bactec system vials have lower sensitivity and 
a longer time for fungal growth than bottles from the 
BactAlert system. there are no appreciable differences 
between these products when using bottles with selective 
media for fungi.179
•   It  is  essential  that  blood  cultures  be  processed  by 
automated systems, which have better sensitivity and 
allow for quicker isolation of the agent.
It is important to remember that there is a direct relationship 
between mortality and the time to onset of treatment of 
candidemia. Accordingly, every effort should be made for early 
recognition of patients with hematogenous candidiasis.102
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Given the low frequency of the occurrence of visceral 
lesions in the majority of adult patients with candidemia, the 
investigation of fungal endocarditis (echocardiography) and 
lesions in other organs (abdominal imaging) should be reserved 
for patients who persist with isolation of Candida in blood 
cultures despite appropriate antifungal therapy or who show 
signs of clinical deterioration and signs/symptoms suggestive 
of infection in the abdominal cavity and/or endocarditis. In 
turn, fundoscopic examination should be performed in all 
patients with candidemia and visual symptoms. In patients 
with candidemia but no visual symptoms, it is recommended 
to perform fundoscopy one week after the initiation of therapy 
to increase the sensitivity of eye lesion detection.102,176
3.  Chronic disseminated candidiasis (CDC): complication 
documented in patients with neutropenia that develop 
suppurative lesions predominantly localized in the 
liver and spleen (but may occur in other organs, 
particularly the kidney) that manifest after the recovery 
of neutrophils and capacity of the host inflammatory 
response. High fever is the most important symptom 
and occurs in almost all patients; it is associated with 
anorexia, weight loss, pain in the right hypochondrium, 
nausea and vomiting. Hepatosplenomegaly is identified 
in half of the cases. A significant increase in serum 
alkaline phosphatase, which can be up to ten times the 
baseline, is the most important laboratory finding for 
CDC diagnosis in suspected patients with persistent 
fever after neutrophil recovery.177
A diagnosis can be confirmed with ultrasound, computerized 
tomography, magnetic resonance imaging or positron emission 
tomography (PEt-Ct) of the abdomen, along with findings of 
swelling of the affected organs and the presence of multiple 
abscesses in the liver, spleen and/or kidneys. Blood cultures are 
usually negative, and if a directed biopsy is conducted, necrotic 
cellular elements can be identified, and fungal elements are 
absent. In this context, microbiological confirmation of the 
process is rarely obtained. In most cases, the patient is treated 
according to the epidemiological and clinical findings, together 
with the laboratory evidence of CDC represented by abscesses in 
abdominal imaging and high levels of alkaline phosphatase.177,180 
It is important to remember that this situation can occur in 
infections by other fungi, including yeast (e.g., Trichosporon) and 
molds (Fusarium, Scedosporium, etc.).
Therapeutic recommendations
the definition of the best therapeutic strategy to be adopted 
for patients with hematogenous candidiasis should consider 
the aspects described below:181
•   Presence of infectious complications in organs: the occurrence 
of endophthalmitis, osteomyelitis, endocarditis and CDC are 
examples of clinical conditions for which antifungal therapy 
should be extended for periods of four weeks to six months. 
If prolonged therapy is needed, oral drugs should be chosen.
•   Severity of  the clinical presentation of  the case:  this  issue 
is controversial, but patients with organ failure are usually 
treated initially with fast-acting antifungal drugs; fluconazole 
is generally saved for a second event when there is an initial 
clinical response and identification of the Candida species.
•   Determination of Candida species: non-albicans species may 
exhibit lower susceptibility to fluconazole, requiring dose 
adjustment or a change in medication.
•   Risk of renal toxicity while using conventional amphotericin 
B: the occurrence of acute renal failure in patients in ICUs 
with renal dysfunction, elderly patients and those receiving 
other nephrotoxic drugs.
•   Previous exposure to antifungal prophylaxis regimens and/or 
empirical therapy: facing a breakthrough infection in a patient 
exposed to an antifungal agent, a change of therapeutic 
class is indicated until the involved Candida species and the 
susceptibility profile of the agent are confirmed.
•   Presence of an intravascular catheter in a central position: 
the clinical management of this aspect will be discussed in 
another section.
•   The need for surgical removal of the infectious focus: cases 
of osteomyelitis and endocarditis are examples of clinical 
situations in which surgical cleaning (or valve replacement) 
should be considered in the therapeutic management of 
patients.
We currently have the following drugs available for the 
treatment of invasive candidiasis: amphotericin B and its 
formulations, fluconazole, voriconazole and echinocandins.
Candidemia in non-neutropenic patients
•   In  the  last  two years,  there have been  important  changes 
in the epidemiology of candidemia. Several medical 
centers have reported fungemia rates greater than 10% in 
adult patients involving species resistant to fluconazole, 
particularly Candida glabrata and Candida krusei.43,170,182
•   Moreover, it is known that the rates of persistent Candida in 
patients treated with fluconazole are far superior to those 
of patients treated with fungicidal antifungal drugs, like 
echinocandins or formulations of amphotericin B.32,35
•   In the only study comparing an echinocandin to fluconazole, 
success rates were significantly higher in patients treated 
with anidulafungin, even in infections susceptible to 
fluconazole (Candida albicans and Candida tropicalis).32
•   However, for the three echinocandins available in the Brazilian 
market, there have been substantial price reductions in the 
daily treatment doses used with this therapeutic class.
•   A patient-level quantitative review of 7 randomized clinical 
trials performed in 1.915 patients with candidemia/invasive 
candidiasis involving three therapeutic classes reported that 
treatment with echinocandins was associated with decreased 
mortality.183
•   Given  the  poor  prognosis  of  this  infection  in  our  country 
(50% associated mortality in most series), the high rate of 
successful clinical and laboratory treatment of candidemia 
when a broad-spectrum antifungal drug with fungicidal 
activity is used from the beginning of treatment, and the lower 
rates of echinocandin toxicity compared to any formulation 
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of amphotericin B, we understand that the best option for 
initial treatment of this infectious complication is one of 
the three echinocandins: anidulafungin (A-I), caspofungin 
(A-I) or micafungin (A-I).30-32 Despite the high MIC values 
observed with echinocandin when tested against Candida 
parapsilosis, therapeutic results are satisfactory in clinical 
trials, with no significant differences regarding success rates 
when compared to infections by other species of Candida.16,34 
However, with persistent positive blood cultures for Candida 
parapsilosis, it is recommended that another class of antifungal 
be started (B-II).
•   The best use of fluconazole should be considered in sequential 
therapy to complete a minimum period of 14 days of 
treatment after determining the etiological agent and upon 
documentation of a favorable clinical response to treatment 
with echinocandins (B-I).184
•   The best use of voriconazole is as an oral sequential therapy 
in patients infected with strains resistant to fluconazole and 
susceptible to voriconazole and as a therapeutic approach 
for patients with central nervous system involvement/
endophthalmitis (B-II).81,192 this product should be contra-
indicated in breakthrough infections after fluconazole therapy 
and/or invasive infections caused by Candida glabrata and 
Candida krusei and in view of the possibility of cross-resistance 
and limited efficacy in this scenario (B-III).44,81
•   In view of the renal toxicity of amphotericin B deoxycholate, 
this drug should be avoided in ICU patients, particularly those 
exposed to conditions or other nephrotoxic drugs (A-I).185
•   Fluconazole may be an alternative therapy in clinically stable 
patients whose infections are considered minor, who were not 
exposed to regimens of prophylaxis with triazoles, and who 
are admitted to medical services exhibiting low incidences of 
infections caused by Candida glabrata and Candida krusei (B-I).186 
Medical centers with rates of incidence exceeding 10% of the 
fluconazole-resistant strains should not use fluconazole in any 
patient before the agent is identified (C-III).
•   Lipid formulations of amphotericin B are an alternative therapy 
for candidemia, but they have greater renal toxicity than 
echinocandins. the only lipid formulation in the treatment of 
Candida assessed in a randomized and comparative study with 
echinocandin was the liposomal formulation of Amphotericin 
B, indicated at a dose of 3 mg/kg/day for the treatment of 
adults (B-I).31
•   The  lipid  complex  of  amphotericin  B  has  been  used  in 
patients with candidemia, but only in open-label non-
comparative studies using doses ranging from 3 mg/kg/day 
and 5 mg/kg/day (B-II).187
•   Lipid  formulations  of  amphotericin  B  are  alternatives  for 
patients who: are unresponsive to echinocandins, are 
intolerant to this therapeutic class, or develop endocarditis or 
meningitis (B-III).102
•   Patients  with  endophthalmitis  may  not  respond  to 
echinocandins, given its low penetration in the eye. In this 
context, better results are expected with fluconazole or 
voriconazole (B-II).175
•   With  respect  to  the  time  of  treatment  in  all  randomized 
trials conducted with antifungal agents in the last decade, 
the duration of antifungal therapy was at least 14 days 
after negative cultures and the disappearance of signs and 
symptoms of hematogenous candidiasis.102 In this sense, 
serial blood cultures must be collected until the infection site 
is negative, and it is recommended to repeat sampling on the 
third and fifth day after initiation of therapy (at a minimum) 
to evaluate the success of the microbial treatment (B-III).102
•   Cases  of  endocarditis,  osteomyelitis,  meningitis,  or  CDC 
require longer treatment; it is very important to check the 
availability of antifungal drugs with good bioavailability for 
oral use (B-II).102
Candidemia in neutropenic patients
•   Patients with neutropenia should be treated with drugs with 
a broad-spectrum antifungal drug with fungicidal activity 
from the beginning of treatment (A-II).188
•   Given  the  risk  of  renal  toxicity  with  conventional 
amphotericin B, this drug should be avoided in this scenario 
(B-I).185
•   Therefore,  echinocandins  (A-I),  liposomal  amphotericin  B 
(B-I) and amphotericin B lipid complex (B-II) are considered 
alternatives.189,190
•   Randomized  trials  of  candidemia  involving  caspofungin 
and micafungin included approximately 10% neutropenic 
patients. Although there are no data on the performance of 
anidulafungin in the treatment of candidemia in neutropenic 
patients, there is no evidence of pre-clinical or clinical order 
to suggest that echinocandins have differences in their rates 
of therapeutic success (B-III).
•   Given  the  higher  incidence  of  infections  caused  by Candida 
glabrata and Candida krusei in patients with cancer, along with 
the fact that large percentages of patients with neutropenia 
are exposed to fluconazole prophylaxis, the recommendation 
is that the primary treatment of candidemia in patients with 
cancer and neutropenia not be performed with triazoles 
(B-II).191
•   The treatment time must meet the same criteria established 
for non-neutropenic patients (B-I).102
•   Infections involving multiple organs or systems must meet the 
same recommendations given for non-neutropenic patients, 
along with care for patients referred for Candida parapsilosis 
candidemia treated with echinocandins (B-II).16,34
Patients with evidence of endophthalmitis
•   All  patients  with  candidemia  should  have  at  least  one 
dilated-eye examination performed by an ophthalmologist 
(A-II).102
•   Upon  diagnosis  of  endophthalmitis,  the  drugs  better 
penetrate into the eyeball are fluconazole and voriconazole 
(B-III).192,193
•   Early  intervention  with  partial  vitrectomy  and/or  an 
intravitreal antifungal may be necessary in severe cases 
(B-III).194
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•   In  these  cases,  we  recommend  antifungal  therapy  for 
a period of four to six weeks, with monitoring by an 
ophthalmologist for further characterization of the time of 
treatment and response to therapy (A-III).102
Patients with evidence of endocarditis
•   In  these  cases,  the  greatest  experience  in  the  literature 
involves systemic therapy with an amphotericin B lipid 
formulation due to the possibility of using high dosages 
(B-II).195
•   Alternatives  include  echinocandin  (B-II),  which  is  very 
active against Candida biofilm and have fungicidal activity 
against most Candida spp. Fluconazole should be used only 
for sequential therapy to complete the target period of 
treatment when the Candida species is susceptible and the 
patient is clinically stable (B-III).196-198
•   Although  amphotericin  B  is  considered  an  effective 
alternative, in view of its potential toxicity and the treatment 
duration required, its use should be avoided (B-II).185
•   A  valve  replacement  is  recommended,  and  systemic 
therapy should continue for at least six weeks after valve 
replacement (B-III).199
Patients with CDC
•   Given the low incidence of this complication, there are no 
comparative data regarding efficacy and tolerability between 
the different antifungals.
•   The treatment of this condition is always long, so it starts with 
a broad-spectrum fungicidal drug until clinical improvement 
is achieved, which is followed by oral fluconazole for three 
to six months (A-III).200
•   The antifungal should be used until complete resolution of 
the abscess, as detected by imaging (A-III).200
•   The  greatest  experience  in  treating  patients  with  CDC 
involves amphotericin B formulations (B-II).200
•   In  case  of  infection  control  and  as  long  as  the  patient 
continues receiving antifungal drugs, there are no 
contraindications for starting a new cycle of chemotherapy 
or for the transplantation of hematopoietic stem cells 
(B-II).201,202
•   Therapeutic  options  are:  amphotericin  B  deoxycholate 
at a dose of 0.6 mg/kg/day to 0.7 mg/kg/day (B-II); an 
amphotericin B lipid formulation at a dose of 3 mg/kg/day 
to 5 mg/kg/day (B-II);203 fluconazole 6 mg/kg/day in stable 
and non-neutropenic patients who have not previously 
used fluconazole (B-II)204,205 and echinocandins in the usual 
doses (B-II).206
•   As  manifestations  of  CRC  result  from  an  exaggerated 
inflammatory response, the use of corticosteroids as an 
adjuvant therapy may be useful. In a series of cases, patients 
who received corticosteroids experienced rapid resolution of 
fever and general symptoms (B-II).207
Management of central venous catheter (CVC)
Most patients with candidemia have one venous catheter in 
the central position upon diagnosis. the reason for removal of 
the CVC in patients with candidemia is the fact that Candida 
can colonize the CVC, producing a biofilm, and lack of removal 
may result in persistence of a focus of infection. Several 
retrospective studies have analyzed the impact of CVC removal 
on outcomes such as duration of candidemia and mortality; 
the majority of these studies reported lower mortality rates 
when the CVC was removed.208-213
these studies form the basis for recommendations to 
remove the CVC in the guidelines of candidemia management 
published in recent years.102 However, these studies have 
several limitations, including the lack of multivariate analysis, 
in particular severity scores, the inclusion of early deaths 
and, most importantly, the absence of setting a time for the 
withdrawal of the CVC.
A recently published study analyzed 842 episodes of 
candidemia in adults and conducted a sub-analysis of two 
randomized trials of candidemia treatment with echinocandins 
(caspofungin or micafungin) or liposomal amphotericin B. We 
investigated the effect of early removal (24 or 48 hours after 
initiation of candidemia treatment) in six outcomes: success 
rate of candidemia treatment, candidemia persistence rate, 
and mortality rates of Candida applicants at 28 and 42 days. 
none of the six outcomes was influenced by early removal of 
the CVC (both in 24 hours and in 48 hours).214 Based on this 
study, adult candidemia and the early removal the CVC (24 to 
48 hours after the start of treatment) cannot be recommended 
if the patient is receiving an echinocandin and liposomal 
amphotericin B (B-II). In this case, removal of the CVC is 
recommended if there is persistent (>72 hours) isolation of 
Candida despite treatment.
However, the group consensus considered waiting 72 hours 
after the initiation of antifungal therapy to define the need 
for removal of the CVC, as this cannot be the recommended 
approach in some scenarios for specific patients. In this 
sense, in non-neutropenic critically ill patients who have 
severe sepsis, as well as in breakthrough cases of candidemia 
in patients receiving more than three days of a systemic 
antifungal agent with activity against the pathogen isolated, 
early removal of the CVC should be considered (C-III).
Empirical therapy
Neutropenic patients
Empirical antifungal therapy is instituted in neutropenic 
patients with fever and neutropenia that persist for a 
period of four to six days after initiation of broad-spectrum 
antibiotics. this practice was instituted in the 1980s and 
1990s, and some randomized trials have been published 
initially testing this strategy after comparing different 
agents.215,216 Acceptable options for empirical therapy that 
have been tested in randomized trials are lipid preparations 
of amphotericin B, caspofungin and voriconazole.217-219 More 
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recently, empirical antifungal therapy has been replaced by 
another strategy called preemptive therapy, which consists of 
starting antifungal therapy because of fever and other signs 
of infection.220 this strategy is more relevant when there is 
suspicion of infection by filamentous fungi (Aspergillus spp., 
Fusarium spp. and others). Some biomarkers have been tested, 
including galactomannan (Aspergillus spp.)221 and 1.3 beta-D-
glucan for Candida spp., Aspergillus spp. and other fungi.222
Regarding invasive candidiasis/candidemia, the most 
important issue to consider in a neutropenic patient with 
persistent fever despite antibiotic therapy is to assess the risk 
of infection. there are three parameters to be evaluated: the 
use of fluconazole in prophylaxis as well as the presence of 
gastrointestinal mucositis and a CVC. In addition to the risk, 
another parameter to be considered is the need for coverage 
of filamentous fungi. Patients with profound neutropenia 
(>100 cells/mm3) lasting more than ten days are those with 
increased risk for developing filamentous fungal infection.220
Recommendations for empirical therapy for candidemia/
invasive candidiasis in neutropenic patients
•   Amphotericin  B  deoxycholate  should  not  be  used 
because these patients often have other risk factors for 
nephrotoxicity, including the underlying disease (e.g., 
multiple myeloma), its treatment (i.e., anticancer drugs, 
tumor lysis syndrome) and the use of other nephrotoxic 
agents (i.e., diuretics, antibiotics) (A-II).185
•   Patients who are  receiving prophylactic fluconazole, do 
not have gastrointestinal mucositis and who are not at 
risk of infection by filamentous fungi may not receive 
empirical antifungal therapy (C-III).223
•   Patients who are not receiving fluconazole and who are 
not at risk of infection by filamentous fungus should 
receive fluconazole (B-I).223
•   Patients who are receiving fluconazole prophylaxis, yet the 
clinician considers the possibility of invasive candidiasis, 
should receive empirical therapy with an agent from 
another therapeutic class (i.e., a lipid preparation of 
amphotericin B or an echinocandin – caspofungin or 
micafungin) (B-II).223
Non-neutropenic patients
Candidemia is an important complication of critically 
ill patients and is associated with high morbidity and 
mortality.224,225 Recent studies have shown that the delay in 
initiating appropriate treatment in patients with candidemia 
significantly increases mortality.226,227
Approximately 40-50% of candidemias occur in patients 
admitted to the ICU. this population of patients has a high 
risk of mortality because they are clinically unstable. thus, 
ICU patients at high risk for candidemia/invasive candidiasis 
may benefit from early initiation of an appropriate antifungal. 
However, unlike in neutropenic patients, empirical therapy 
has not been adequately tested in non-neutropenic patients, 
as there are no validated tools to identify patients at risk 
and because it is difficult to define outcomes to assess the 
effectiveness of the therapy.
Despite these limitations, some attempts have been made 
to identify patients with invasive candidiasis in units of 
severely ill patients.228-232 these scoring systems use clinical 
information with or without data from Candida colonization 
and yielded a reasonable correlation with the occurrence of 
candidemia/invasive candidiasis. More recently, two biological 
markers have been tested for the early diagnosis of candidemia/
invasive candidiasis: 1-3 beta-D-glucan and PCR. In a study in 
surgical patients, the evaluation of 1-3 beta-D-glucan in the 
plasma of patients colonized with Candida was useful to trigger 
the onset of empirical antifungal.233 In another study, a PCR 
assay was tested in 225 patients at high risk for candidemia. 
Using blood culture as the gold standard, the sensitivity and 
specificity of PCR were 72.1 and 91.2%, respectively.234
Recommendations for empirical therapy for candidemia/
invasive candidiasis in non-neutropenic patients
•   Physicians should consider the use of empirical antifungal 
therapy in critically ill patients with risk factors for 
candidemia and clinical manifestations of infection that 
are not responding to treatment for bacterial infections 
(C-III).
•   The  choice  of  antifungal  drug  for  empirical  therapy 
should be based on the same criteria for the selection 
of appropriate antifungal treatment for candidemia (see 
specific section).
•   To support the clinician in the task of selecting patients for 
empirical antifungal therapy, as experts, it is our opinion 
that this therapeutic strategy has a greater chance of 
success when used in ICU patients with sepsis that is 
unresponsive to antibiotics (excluding other causes of 
FoI) who have been exposed to three or more risk factors 
for candidemia for at least 4 to 7 days of intensive care, 
particularly those with Candida colonization in non-
sterile sites and a history of major surgery in the last 2 
weeks (C-III).
Prophylaxis
Neutropenic and hematopoietic stem cell transplant patients
Invasive candidiasis/candidemia is a frequent complication 
in neutropenic patients and recipients of hematopoietic stem 
cell transplants (HSCts) who do not receive prophylaxis. In 
neutropenic patients, the frequency varies depending on 
the patient receiving chemotherapy. the risk factors include 
neutropenia, the use of a CVC and primarily gastrointestinal 
mucositis.235 thus, patients receiving intensive chemotherapy 
are those with increased risk of developing invasive candidiasis. 
In HSCt, invasive candidiasis/candidemia typically occurs in 
two stages: first, early after transplantation, the risk factors are 
the same as patients receiving chemotherapy, as in this phase, 
they also have a catheter and neutropenia, and mucositis may 
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develop. After the recovery of the blood marrow, autologous HSCt 
recipients rarely develop invasive candidiasis/candidemia. the 
receptors of allogeneic hematopoietic stem cell transplantation 
can present with invasive candidiasis if they develop chronic 
graft-versus-host disease (GVHD) in the GI tract. 
Several randomized trials testing different agents have been 
developed for prophylaxis of invasive candidiasis/candidemia 
in patients receiving both chemotherapy and HSCt. the 
agents that exhibited efficacy were fluconazole, itraconazole 
oral solution (but not capsules), voriconazole, posaconazole, 
micafungin, caspofungin and intravenous amphotericin B. 
However, many studies have shown no benefits, either due to 
methodological problems (low numbers of patients) or because 
the study population had a high risk of developing invasive 
candidiasis.236
Recommendations for prophylaxis for candidemia/
invasive candidiasis in neutropenic patients receiving 
HSCT
a) HSCt
•   Fluconazole  is  the  drug  of  choice  for  prophylaxis  of 
invasive candidiasis in the period of neutropenia in 
recipients of allogeneic HSCt and can be established at 
the beginning or the end of the conditioning regimen 
(A-I).237,238 the standard dose is 400 mg/day, but there is 
evidence in a randomized study that 200 mg/day is also 
effective (B-I).239
•   An alternative to fluconazole  is micafungin, but  its use 
is limited by the need for venous access and its high 
cost (B-I).240
•   Itraconazole oral solution (not available in Brazil) was also 
effective, but its use is limited by the high frequency of 
gastrointestinal side effects (C-I).241,242
•   Voriconazole  is  an  alternative  that  can  be  used  when 
you need coverage for filamentous fungi based on a 
comparative study with fluconazole (B-I).243
•   Options  for  prophylaxis  of  invasive  candidiasis  in  the 
post-picks are voriconazole and posaconazole (B-I).244,245
•   The risk of invasive candidiasis/candidemia is much lower 
in recipients of autologous HSCt. thus, prophylaxis is 
not routinely recommended (C-III). However, prophylaxis 
(fluconazole) may be indicated in some situations, 
such as when manipulation of the graft occurs, when 
severe mucositis is expected, in patients who received 
fludarabine or cladribine or in those with MBL (mannose-
binding lectin) deficiency (B-III).172
b) neutropenia
•   The  results  of  randomized  trials  testing  fluconazole 
in neutropenic patients are not as effective as in 
HSCt, especially because this population is more 
heterogeneous.236 In general, the more intensive 
the chemotherapy regimen is, the higher the risk of 
invasive candidiasis. thus, patients with acute myeloid 
leukemia/myelodysplasia receiving remission induction 
chemotherapy may benefit from prophylaxis. Although 
fluconazole is the drug of choice for the prevention of 
invasive candidiasis, these patients also have a high risk 
of filamentous fungi; thus, posaconazole (200 mg orally 
three times a day) may be preferred (A-I).245
•   For  the prevention of  invasive candidiasis,  itraconazole 
oral solution (not available in Brazil) can be used, but 
it has the limitation of gastrointestinal toxicity (C-I). In 
a meta-analysis of 13 randomized trials, itraconazole 
oral solution also prevented the occurrence of invasive 
aspergillosis, and in ten studies, tCtH receptors were 
also included.246
•   Caspofungin was also tested in a randomized study; it is 
an option, with the exception of requiring venous access 
for administration (C-I).247
•   Prophylaxis  for  invasive  candidiasis/candidemia  in 
situations out of remission induction for acute myeloid 
leukemia/myelodysplasia is not routinely recommended 
(C-III). However, in special situations, such as after remission 
induction regimens for acute lymphoid leukemia in a high 
risk patients, prophylaxis may be useful (C-III).
Solid organ transplanted patients
Solid organ transplant recipients represent a set of hosts 
susceptible to infectious events, which result from the interaction 
between endogenous immunosuppression (i.e., uremia, diabetes, 
liver failure), iatrogenic immunosuppression (resulting from the 
use of medications to prevent rejection episodes) and surgical 
procedures and their inherent risks. Among infectious events, 
fungal infections are important because they usually depend on 
many immunodepression states.
However, the group of transplanted solid organs is 
heterogeneous with respect to the variables that lead to 
immunosuppression and, therefore, with respect to the actual 
state of the resulting immunosuppression, which leads to 
different rates of fungal infection and different prevalence, 
including Candida infections.
Epidemiology, clinical significance and 
recommendations for prophylaxis for candidemia/
invasive candidiasis in solid organ transplant patients
Kidney transplantation
Renal transplantation is the most frequent solid organ 
transplantation and the least technically complex from the 
surgical point of view because it is an extraperitoneal surgery 
of short duration.
Renal transplantation is the solid organ transplantation 
with the lowest rate of invasive Candida infections and the 
one in which the clinical repercussion is least significant. 
Approximately 50% of yeast infections are caused by Candida 
species. of these, over 70-80% represent urogenital infections 
(especially candiduria, which occurred in 11% of patients in 
a retrospective study) or esophagogastric infections. only 0.5 
to 5% of the infections occur in the form of candidemia or 
disseminated candidiasis.248
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the most prevalent infections (i.e., urinary tract infection 
and esophagitis) are associated with low morbidity and are 
infections of secondary importance in the spectrum of fungal 
infections in kidney transplants.
Due to the benign nature of Candida infections in this 
group and the low rate of candidemia, there is no formal 
recommendation for chemoprophylaxis. 
Exceptions are made for situations in which there 
is a urinary tract infection in the donor at the time of 
transplantation because there are anecdotal reports of 
transmission to the donor with serious consequences (i.e., 
loss of graft anastomosis). Prophylaxis depends on exact 
timing, and single-agent treatment is not established (C-III).249
Liver transplantation
Liver transplantation, the second most frequent solid organ 
transplantation, is related to high rates of fungal infections (30-
40%) mainly due to the complexity of the surgical procedure, 
which requires an approach through the abdominal cavity and 
often the bowel, factors known to be related to the occurrence 
of Candida infections.
Among fungal infections, Candida infections represent 80% 
of the total events, and candidemia (40%), peritonitis and 
intracavitary abscesses are the most common manifestations. 
Most events occur before the sixth post-transplant month, 
and there has been a reduction in the frequency of Candida 
over the past years, which has been attributed to improved 
practices and surgical results.250
Risk factors that distinguish patients at higher risk for 
invasive candidiasis are retransplantation, dialysis and kidney 
failure, the need for large volumes of blood products during 
surgery, antibiotic therapy before transplantation and biliary-
enteric anastomosis.250
Contrary to what is observed following kidney transplants, 
invasive Candida infections are associated with reduced patient 
survival and considerable morbidity. 
In this patient population, randomized, placebo-controlled 
trials have attempted to reduce invasive candidiasis, reflecting 
the importance of the event. At least six randomized trials 
(using fluconazole, itraconazole or liposomal amphotericin) 
and a meta-analysis of these combined studies are available 
in the medical literature.251
the results of this meta-analysis, which involved total 
transplanted groups (with no selection criteria for special 
groups or subgroups) show total reduction of fungal infections, 
particularly invasive fungal infections (without specific 
reference to reducing candidemia), consistent with the results 
of each individual study and regardless of the antifungal agent 
used. However, a reduction in mortality was not demonstrated. 
According to the authors, there is a need for treatment of 11.8 
organ transplant recipients in order to prevent one invasive 
fungal infection.251
Some authors, having identified heterogeneity in patients 
and the presence of specific risk factors that identify high-risk 
populations, advocate focusing on this population as a target for 
prophylactic therapy.252 However, these recommendations are 
based on observational and uncontrolled studies, decreasing 
the strength of the recommendation. 
the focus on higher-risk patients is bolstered by the 
demonstration (from controlled studies) that prophylaxis can 
lead to side effects, such as the selection of non-albicans strains 
with greater potential for resistance to azoles.
With the above data available, it is the opinion of this 
consensus group that antifungal prophylaxis is recommended 
in liver transplant recipients at greatest risk, recognizing its 
clinical importance, frequency and the difficulty of establishing 
the diagnosis in advance. According to the criteria of cost, 
toxicity and acceptance, we also recommend the use of 
fluconazole as the drug of choice.253
Find below the specific recommendations of this consensus.
•   Patients  at  risk  for  whom  prophylaxis  should  be 
recommended in the first month after transplantation: 
the existence of at least two of the following risk factors in 
the first month after transplantation: retransplantation, 
the need for dialysis, the use of antibiotics and wide 
biliary-enteric anastomosis (B-II).
•   Prophylactic  scheme:  fluconazole  200  mg  (minimum 
dose) IV with the possibility of using orally for up to three 
months, individualized according to the patient’s clinical 
condition (i.e., state of immunosuppression, presence in 
ICU and persistence of risk factors) (B-II).
•   Using  this  strategy,  monitor  the  levels  of  calcineurin 
inhibitors (tendency to increase in serum) and check for 
interactions with other azoles (A-II).
Pancreas/kidney transplantation
this transplantation modality is also frequently associated 
with fungal infections because it is performed in diabetic 
patients and also because of the complexity of the surgery, 
which involves handling of the intestinal tract.
over 90% of events are caused by Candida species in the form 
of intra-abdominal infections with or without concomitant 
candidemia. As is the case with liver transplantation, invasive 
Candida infections are associated with both reduced grafts and 
patient mortality.254
Although the frequency and clinical impact of Candida 
infections are very similar with respect to what occurs in liver 
transplantation, there are no randomized studies evaluating the 
effectiveness of prophylactic antifungal drugs. there are also 
no studies reporting specific risk factors for the occurrence of 
fungal infections in this group of transplant recipients. there is 
only one controlled observational study with historical groups 
showing lower rates of Candida infections with fluconazole 
400 mg/day for seven days. the practice is widespread in 
groups that perform pancreatic transplantation, and there is 
currently little room for the proposition of controlled studies 
with placebo.255
It is the opinion of this consensus that prophylaxis should 
be restricted, recognizing the importance of the event and to 
curb the excessive use of prophylaxis. Fluconazole can be used 
in a similar scheme to that used for liver transplantation (C-II).
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Thoracic transplantation (heart, lung, heart/lung)
In this group of patients, infections occur in 2.2% of patients 
undergoing heart transplantation and in 9% of patients 
undergoing lung or heart/lung transplantation. However, unlike 
what happens with other types of solid organ transplantations, 
there is a high prevalence of infections by filamentous fungi with 
high mortality. Candida infections correspond to 30% of fungal 
infections, mainly in the form of hematogeneous candidiasis.256
the low incidence of serious fungal infections in heart 
transplant does not indicate the use of specific prophylaxis in 
this population.
With respect to lung transplantation, the focus is to prevent 
the occurrence of filamentous fungi; preventing Candida infection 
is a less-important goal. thus, this consensus does not suggest 
prophylaxis for Candida in this group of patients but reinforces 
the importance of anti-Aspergillus prophylaxis, which has been 
adopted by 75% of lung transplan tation centers.257
Intestinal transplantation
Intestinal transplants are performed infrequently but are 
associated with high rates of Candida infections by extensive 
manipulation of the intestinal tract.
Data are scarce regarding prophylaxis in this group; 
treatment with fluconazole should be considered in high-risk 
patients.
General recommendations
•   There  is  no  indication  for  routine  prophylaxis  against 
Candida in renal transplant patients (B-II).
•   There is evidence for the use of prophylaxis for Candida 
in liver transplantation with reduction in invasive events 
but not in mortality (B-II).
•   Liver transplant patients should receive prophylaxis with 
fluconazole for one to three months (B-II).
•   The same level of evidence exists for the use of fluconazole 
in kidney/pancreas or intestinal transplants, but the use 
of fluconazole is suggested for high-risk patients (C-III).
•   There  is  no  indication  for  routine  prophylaxis  against 
Candida in transplanted heart and/or lung patients (B-II).
Non-neutropenic patients in the ICU
there are four randomized and well-designed clinical 
trials illustrating the benefit of the use of fluconazole in 
terms of reduction of invasive Candida infection in the ICU, 
particularly for surgical patients. Despite studies that show 
the effectiveness of prophylaxis with fluconazole in terms of 
reduction of invasive Candida infections (but not mortality), 
it is not possible to establish criteria that are universally 
applicable for the selection of patients undergoing prophylaxis 
with this triazole. this fact is due to the large heterogeneity 
of clinical characteristics in patients admitted to the ICU from 
different medical centers and the variations in the incidence 
rates of candidemia in hospitals. Whereas most medical 
centers have incidence rates of candidemia on the order of 
1% among patients in the ICU, 100 to 200 critically ill patients 
must be exposed to prophylaxis with fluconazole to prevent 
one episode of candidemia. In this context, until new criteria 
for selecting patients at high risk (chance >10% for event) 
for candidemia are validated, this practice has questionable 
benefits, as it is associated with increased risk for adverse 
effects; it also contributes to the development of resistance to 
triazoles and can lead to increased health care costs.258, 259, 260
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Appendix 1
Therapeutic regimens for Candidiasis
Site Therapy Level of evidence Comments
Oral candidiasis Topic
nystatin 100.000 UI/mL to 400.000 UI/mL or 4 mL to  
6 mL 4 to 5 times/day for 14 days
Systemic
Fluconazole Po 200 mg at first day and 100 mg/day for 
7 to 14 days
Itraconazole Po 200 mg BID with food for 7 to 14 days
Voriconazole 200 mg BID for 7 to 14 days
B-II
A-I
A-II
B-II
Low tolerance and high levels of sugars, 
such as in vehicles (cariogenic potential 
and caution in diabetics)
therapy with capsules has the 
disadvantage of absorption problems and 
reduced exposure of the antifungal agent 
in saliva
Esophageal candidiasis Fluconazole Po or IV 200 mg in the first day followed by 
100 mg/day for 14 to 21 days
Voriconazole 200 mg BID for 14 to 21 days
Itraconazole 200 mg Po BID with food for 14 to 21 days
Amphotericin B deoxycholate 0.3 mg/kg/day to  
0.5 mg/kg/day IV for 7 to 14 days
Caspofungin 50 mg/day IV or anidulafungin 100 mg/day 
IV or micafungin 150 mg/day IV for 7 to 14 days
A-I
A-I
B-II
B-II
A-I
Use in the treatment of oropharyngeal 
candidiasis refractory to fluconazole is 
based on studies in vitro, but there is little 
documentation of their clinical success in 
this specific condition
therapy with capsules has the 
disadvantage of absorption problems and 
reduced exposure of the antifungal agent 
in saliva
Vulvovaginal candidiasis Topical
topical therapy with azoles for 3 to 7 days or nystatin 
for 10 to 14 days:
•   Butaconazole 2% cream, 5 g/day.
•   Clotrimazole 1% cream, 5 g/day
•   Clotrimazole vaginal tablets, 500 mg/day
•   Miconazole 2% cream, 5 g/day
•   Miconazole 100 mg, 200 mg or 1.200 mg  
(single dose) vaginal suppositories 
•   Econazole 150 mg tablets or suppository 
•   Terconazole 0.4% or 0.8% cream, 5 g/day
•   Terconazole vaginal suppositories, 80 mg
•   Nystatin vaginal tablets, 100.000 UI  
(for 10 to 14 days)
Systemic
Fluconazole single dose 150 mg Po
Itraconazole Po 200 mg/day for 3 days or 400 mg Po 
single dose
Complicated dose
Fluconazole 150 mg/day repeated 2 to 3 times 72 hours 
apart
Itraconazole 200 mg/day for 3 days
Recurrent cases
Suppressive therapy for 6 months with triazoles
therapy with vaginal suppositories of boric acid 600 
mg/day for 14 days is indicated for recurrent candidiasis 
caused by Candida glabrata
A-I
A-I
B-II
A-I
B-II
A-I
B-I
the treatment of sexual partners is not 
recommended in uncomplicated cases 
but may be considered in women with 
recurrent form
See dosage and formulation in the text
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Site Therapy Level of evidence Comments
Urinary candidiasis Fluconazole IV or Po 200 mg/day for 7 to 14 days
Systemic amphotericin B 0.3 mg/kg to 1 mg/kg/day for 
1 to 7 days
Amphotericin B in bladder irrigation, 50 mg/day for 
48 to 72 hours in a continuous infusion with a 2-way 
catheter
A-I
B-II
B-II
these regimens are reserved for 
refractory cases or cases intolerant to 
a fluconazole and for yeasts that are 
resistant to this azole
Peritoneal candidiasis related to dialysis Systemic amphotericin B 0.7 mg/kg/day to 1 mg/kg/day
Fluconazole IV or Po 400 mg/day
B-II
B-II
treatment period must be four to six 
weeks
Postoperative peritoneal candidiasis Systemic Amphotericin B 0.7 mg/kg/day to 1 mg/kg/day
Fluconazole IV or Po 400 mg/day
Echinocandins
B-II
B-II
B-I
Respiratory tract candidiasis Upon confirmation of a diagnosis of pneumonia, the 
choice of antifungal should be made as discussed in 
the section on acute disseminated candidiasis; there 
may be choice between echinocandins, fluconazole or 
amphotericin B formulations
B-II the finding of a positive culture 
for Candida spp. in respiratory tract 
samples should be taken as evidence of 
colonization of this site, where the risk of 
pneumonia is generally low
Hematogenous candidiasis Non-neutropenic patients
Anidulafungin IV 200 mg at first day followed by  
100 mg/day IV
Caspofungin 70 mg IV at first day followed by  
50 mg/day IV
Micafungin EV 100 mg/day
Fluconazole IV 800 mg/day at first day followed by  
400 mg/day
Amphotericin B liposomal formulation 3 mg/kg/day
Amphotericin B in lipidid complex from 3 mg/kg/day to 
5 mg/kg/day
A-I
A-I
A-I
B-I
B-I
B-II
Considered for sequential therapy to 
complete the minimum period of 14 days 
of treatment after the definition of the 
agent and upon favorable documentation 
of clinical response to treatment with 
echinocandins. Medical centers with 
rates of incidence exceeding 10% of 
fluconazole-resistant strains should not 
use fluconazole in any patient before the 
identification of the agent
A liposomal formulation and 
amphotericin B are alternatives for 
patients who are not responsive to 
echinocandins, who are intolerant to 
the therapeutic class or who develop 
endocarditis or meningitis 
the duration of antifungal therapy 
should be at least 14 days after negative 
cultures and the disappearance of signs 
and symptoms related to hematogenous 
candidiasis
(Cont.)
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Site Therapy Level of evidence Comments
Hematogenous candidiasis Neutropenic patients
Echinocandins 
Amphotericin B liposomal formulation
Amphotericin B in lipidid complex 
Evidence of endophthalmitis
Fluconazole 
Voriconazole
Evidence of endocarditis
Amphotericin B in Lipid formulation (1st choice)
Echinocandins (alternative)
Fluconazole (sequential use)
Chronic disseminated candidiasis 
Amphotericin B deoxycholate 0.6 mg/kg/day to  
0.7 mg/kg/day
Amphotericin B lipid formulation 3 mg/kg/day to  
5 mg/kg/day
Fluconazole 6 mg/kg/day in stable and non-neutropenic 
patients, with no previous use of fluconazole
Echinocandins in regular dosage
A-I
B-I
B-II
B-III
B-III
B-II
B-II
B-II
B-II
B-II
B-II
B-II
the doses and treatment time should 
meet the same criteria established for 
non-neutropenic patients
Antifungal therapy is recommended for 
a period of 4-6 weeks, with monitoring 
by an ophthalmologist for further 
characterization of the treatment time 
and treatment response 
Fluconazole should be used when 
Candida species are susceptible and 
the patient is clinically stable, always 
after a long period of treatment with 
formulations of amphotericin or 
echinocandin
Valve replacement is recommended, and 
systemic therapy should continue for at 
least 6 weeks after valve replacement 
the antifungal should be used until 
complete resolution of the abscesses 
identified in imaging
(Cont.)
